

The Jackson Laboratory

## The Mouseion at the JAXlibrary

---

Faculty Research 2021

Faculty Research

---

7-20-2021

### Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.

Christopher J Terranova

Ming Tang

Mayinuer Maitituoheti

Ayush T Raman

Archit K Ghosh

*See next page for additional authors*

Follow this and additional works at: <https://mouseion.jax.org/stfb2021>



Part of the [Life Sciences Commons](#), and the [Medicine and Health Sciences Commons](#)

---

---


## Authors

Christopher J Terranova, Ming Tang, Mayinuer Maitituoheti, Ayush T Raman, Archit K Ghosh, Jonathan Schulz, Samirkumar B Amin, Elias Orouji, Katarzyna Tomczak, Sharmistha Sarkar, Junna Oba, Caitlin Creasy, Chang-Jiun Wu, Samia Khan, Rossana Lazcano, Khalida Wani, Anand Singh, Praveen Barrodia, Dongyu Zhao, Kaifu Chen, Lauren E Haydu, Wei-Lien Wang, Alexander J Lazar, Scott E Woodman, Chantale Bernatchez, and Kunal Rai

---

# Reprogramming of bivalent chromatin states in *NRAS* mutant melanoma suggests PRC2 inhibition as a therapeutic strategy

## Graphical abstract



## Authors

Christopher J. Terranova, Ming Tang, Mayinuer Maitituoheti, ..., Scott E. Woodman, Chantale Bernatchez, Kunal Rai

## Correspondence

krai@mdanderson.org

## In brief

Terranova et al. provide a comprehensive epigenome resource for melanoma encompassing 284 chromatin maps. They find key regulatory roles for bivalent and broad domains in expression of pro-metastatic genes and identify EZH2 plus MEK inhibition as a therapeutic strategy for *NRAS* mutant melanomas.

## Highlights

- *NRAS* and *BRAF* genotypes display differential patterns of bivalent and broad domains
- Key EMT regulators are likely activated by shifts in bivalent domains
- Broad H3K4me3 domains associate with pro-metastatic drivers and cell-identity genes
- *NRAS* mutants show enhanced sensitivity to combination of EZH2 plus MEK inhibition



## Article

# Reprogramming of bivalent chromatin states in *NRAS* mutant melanoma suggests PRC2 inhibition as a therapeutic strategy

Christopher J. Terranova,<sup>1,14</sup> Ming Tang,<sup>1,10,14</sup> Mayinuer Maitituoheti,<sup>1,14</sup> Ayush T. Raman,<sup>1,7,8</sup> Archit K. Ghosh,<sup>1</sup> Jonathan Schulz,<sup>1</sup> Samir B. Amin,<sup>1,6</sup> Elias Orouji,<sup>1,11</sup> Katarzyna Tomczak,<sup>1</sup> Sharmistha Sarkar,<sup>1</sup> Junna Oba,<sup>3</sup> Caitlin Creasy,<sup>3</sup> Chang-Jiun Wu,<sup>1</sup> Samia Khan,<sup>12</sup> Rossana Lazcano,<sup>12</sup> Khalida Wani,<sup>12</sup> Anand Singh,<sup>1</sup> Praveen Barrodia,<sup>1</sup> Dongyu Zhao,<sup>9</sup> Kaifu Chen,<sup>13</sup> Lauren E. Haydu,<sup>5</sup> Wei-Lien Wang,<sup>2</sup> Alexander J. Lazar,<sup>2</sup> Scott E. Woodman,<sup>1,3,4</sup> Chantale Bernatchez,<sup>3</sup> and Kunal Rai<sup>1,15,\*</sup>

<sup>1</sup>Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

<sup>2</sup>Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

<sup>3</sup>Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

<sup>4</sup>Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

<sup>5</sup>Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

<sup>6</sup>The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA

<sup>7</sup>Epigenomics Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

<sup>8</sup>Graduate Program in Quantitative Sciences, Baylor College of Medicine, Houston, TX 77030, USA

<sup>9</sup>Houston Methodist Academic Institute, Methodist Hospital Research Institute, Houston, TX 77030, USA

<sup>10</sup>FAS informatics, Department of Molecular Biology, Harvard, Cambridge, MA 02138, USA

<sup>11</sup>Epigenetics Initiative, Princess Margaret Genomics Centre, Toronto, ON M5G 2C1, Canada

<sup>12</sup>Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

<sup>13</sup>Department of Cardiology, Boston Children's Hospital, Boston, MA 02115, USA

<sup>14</sup>These authors contributed equally

<sup>15</sup>Lead contact

\*Correspondence: [krai@mdanderson.org](mailto:krai@mdanderson.org)  
<https://doi.org/10.1016/j.celrep.2021.109410>

## SUMMARY

The dynamic evolution of chromatin state patterns during metastasis, their relationship with bona fide genetic drivers, and their therapeutic vulnerabilities are not completely understood. Combinatorial chromatin state profiling of 46 melanoma samples reveals an association of *NRAS* mutants with bivalent histone H3 lysine 27 trimethylation (H3K27me3) and Polycomb repressive complex 2. Reprogramming of bivalent domains during metastasis occurs on master transcription factors of a mesenchymal phenotype, including *ZEB1*, *TWIST1*, and *CDH1*. Resolution of bivalency using pharmacological inhibition of EZH2 decreases invasive capacity of melanoma cells and markedly reduces tumor burden *in vivo*, specifically in *NRAS* mutants. Coincident with bivalent reprogramming, the increased expression of pro-metastatic and melanocyte-specific cell-identity genes is associated with exceptionally wide H3K4me3 domains, suggesting a role for this epigenetic element. Overall, we demonstrate that reprogramming of bivalent and broad domains represents key epigenetic alterations in metastatic melanoma and that EZH2 plus MEK inhibition may provide a promising therapeutic strategy for *NRAS* mutant melanoma patients.

## INTRODUCTION

Melanoma is a deadly disease with an estimated 100,000 new cases each year in the United States (Lens and Dawes, 2004; Miller and Mihm, 2006). While targeted therapy and immunotherapy have become the standard of care with significant improvement in clinical response, thousands of patients still succumb to this disease per year due to primary or acquired resistance (Rosenberg et al., 2011; Tawbi et al., 2018).

Large-scale efforts from consortiums such as The Cancer Genome Atlas (TCGA) have provided deeper understanding of

molecular aberrations in metastatic melanoma (Cancer Genome Atlas Network, 2015; Hodis et al., 2012; Tsao et al., 2012). These studies identified critical somatic mutations in this disease that likely occur due to UV exposure. Among these, somatic mutations in important bona fide oncogenes and tumor suppressors, such as *BRAF*, *NRAS*, *NF1*, *INK/ARF*, *PTEN*, and *TP53*, are well-chronicled drivers of this malignancy (Cancer Genome Atlas Network, 2015; Hodis et al., 2012; Tsao et al., 2012). One of the important findings from these studies was genetic aberrations in several key epigenetic regulators such as *EZH2*, *IDH1/2*, *ARID2*, *KMT2C*, and *KMT2D* (Cancer Genome Atlas Network,



2015; Hodis et al., 2012; Tsao et al., 2012), many of which are enzymes that control the covalent modifications of histones (Ceccarelli et al., 2016; Hodis et al., 2012; Ortega-Molina et al., 2015; Simon and Lange, 2008; Vallianatos and Iwase, 2015; Wu and Roberts, 2013). Although recent studies provide insight into the correlation of isolated chromatin modifiers and histone marks, there are a myriad of possible combinatorial patterns of histone modifications, and it is these combinatorial states—not individual modifications—that dictate epigenetic status of associated genomic loci (Lin et al., 2016; Lomber et al., 2018; Roe et al., 2017). These observations suggest that epigenetic alterations, including those in histone modifications, may play important roles in melanoma progression. Indeed, specific functional roles have been assigned to histone variants such as macroH2A and H2A.z in melanoma (Kapoor et al., 2010; Vardabasso et al., 2015).

Taken together, these studies provide a strong rationale for systematic mapping of the epigenome to obtain a comprehensive understanding of regulatory elements that may act as driver events in particular melanoma tumors. This concept has been epitomized by DNA methylation studies in a large number of tumors profiled by TCGA. For example, a hypermethylation phenotype, termed CpG island methylation phenotype (CIMP), is a common epigenetic feature in various cancer types and tightly associated with critical driver gene mutations (i.e., *IDH1*) (Ceccarelli et al., 2016; Noushmehr et al., 2010; Weisenberger, 2014). Furthermore, other projects, such as ENCODE and Roadmap Epigenomics, have cataloged extensive histone modification in normal human tissues and cell lines. These studies provide critical information regarding tissue-specific regulatory elements, the link between relevant cell types and distinct human traits, and insight for evaluating the epigenetic basis of human diseases (ENCODE Project Consortium, 2012; Kundaje et al., 2015). Importantly, chromatin state mapping in a large number of tumors and cancer cell lines has the potential to enhance these concepts by identifying these regulatory features directly in a disease model (Corces et al., 2018). Since epigenetic aberrations are reversible by targeting their enzyme regulators, chromatin profiling can further identify therapeutic strategies in specific genetic or phenotypic contexts. For example, our previous study suggested histone deacetylase (HDAC) inhibitors could be a good strategy to block the initiation of pre-malignant to malignant melanoma in cell line systems (Fiziev et al., 2017).

During normal development histone modifications work in concert with other chromatin modifiers and transcription factors (TFs) to control the spatial and temporal regulation of gene expression patterns (Dambacher et al., 2010; Sarmento et al., 2004). In this context, the identity of each cell type, and its associated gene expression pattern, is maintained and subsequently inherited by daughter cells through mechanisms that do not alter the DNA sequence (Dambacher et al., 2010; Sarmento et al., 2004). Bivalent chromatin domains are characterized by the concurrent enrichment of active (i.e., Histone H3 lysine 4 trimethylation [H3K4me3]) and repressive (i.e., H3K27me3) histone modifications (Bernstein et al., 2006). During organogenesis, switches in bivalent domains can rapidly control the expression of critical lineage-specific genes that gain or lose these modifications as cells differentiate toward a particular phenotype (Bernstein


et al., 2006; Voigt et al., 2013). In normal cells, bivalent marks are found at cancer-related genes (i.e., *CDKN2A*) with roles specific to the development of those tissues (Jadhav et al., 2016). Hence, it is plausible these genes were active during organogenesis, and an aberrant TF or epigenetic modification can leave them vulnerable to transcription in adult cells. Indeed, these studies have suggested tissue-specific mechanisms recruit histone methyltransferase Polycomb repressive complex 2 (PRC2) to place H3K27me3 at gene promoters in order to avoid unwanted mRNA expression (Jadhav et al., 2016). In melanoma tumors, H3K27me3 and Enhancer of zeste homolog 2 (EZH2) are predominantly expressed at the invasion front and have been linked to an invasive, epithelial-mesenchymal transition (EMT)-associated phenotype (Hoffmann et al., 2020). However, the role of bivalent H3K27me3 chromatin states and the involvement of PRC2 in metastatic melanoma have yet to be described.

In this study, we present a comprehensive chromatin state analysis of metastatic melanoma by performing chromatin immunoprecipitation sequencing (ChIP-seq) of 6 core histone modification marks using 46 melanoma tumors and cell lines. By integrative analysis of various omic datasets, we identify bivalent H3K27me3 and exceptionally wide H3K4me3 domains as potential drivers of a mesenchymal phenotype in metastatic melanoma, primarily in the *NRAS* mutant population. Mechanistically, the misappropriation of bivalent chromatin domains and increased levels of polycomb protein SUZ12 in *NRAS* mutant melanomas provide a plausible mechanism for the deregulation of pro-mesenchymal gene expression. Therapeutically, we demonstrate that the combination of EZH2 plus Mitogen-activated protein kinase kinase (MEK) inhibitors markedly reduces tumor burden in *NRAS* mutant cells, but not *BRAF* mutant cells. Thus, we provide evidence for genotype-dependent epigenome reprogramming in melanomas and show that disruption of PRC2 in combination with MEK inhibition may provide a promising therapeutic strategy for *NRAS* melanoma patients.

## RESULTS

### Bivalent H3K27me3 chromatin domains are enriched in metastatic melanoma

Chromatin state profiling remains a powerful tool for determining the regulatory status of annotated genes and identifying *de novo* elements in non-coding genomic regions (Kundaje et al., 2015). We identified enhancers (H3K27ac and H3K4me1), promoters (H3K4me3), actively transcribed loci (H3K79me2), polycomb silenced loci (H3K27me3), and heterochromatin (H3K9me3) elements in 46 melanoma samples by ChIP-seq using a high-throughput ChIP-seq protocol adapted for tumor tissues (Terranova et al., 2018). These constituted 20 metastatic melanoma tumors (TCGA [Cancer Genome Atlas Network, 2015]), 10 patient-derived melanoma short-term cultures (MSTCs; passage  $n < 10$ ; profiled by internal effort at MD Anderson; unpublished data), and 16 established melanoma lines profiled by the Cancer Cell Line Encyclopedia/Sanger (CCLE) (Barretina et al., 2012) (Table S1). Using our cohort of 20 metastatic melanoma tumor samples, we computed multiple chromatin state models (2-state through 30-state models) with the ChromHMM algorithm (Figures 1A and S1A). We annotated an 18-state model since it is



(legend on next page)

large enough to identify non-redundant functional elements encompassing canonical chromatin states that were not captured using lower state models (Figure S1A). These included such states as active promoters (E1); genic (E5, E6) and active enhancers (E7, E8) harboring high levels of H3K27ac and H3K4me1; and heterochromatic (E10) or polycomb (E14)-based repression harboring high levels of either H3K9me3 or H3K27me3, respectively (Figures 1A and S1B). We also observed two prominent bivalent/poised states: first, harboring both H3K4me3 and high levels of H3K9me3 (E12, annotated as “poised H3K9me3”); and second, H3K4me3 and high levels of H3K27me3 (E13, annotated as “poised H3K27me3”). Overall, the chromatin state profiles in metastatic melanoma tumors are associated with gene expression patterns (Figure 1B). As expected, active chromatin states (E1–E8) are associated with high gene expression levels, whereas repressed states (E10 and E15) are associated with low gene expression levels (Figure 1B).

This TCGA tumor cohort is inclusive of well-described melanoma subgroups (Cancer Genome Atlas Network, 2015), including mutation (*BRAF*, *NRAS*, WT), transcriptomic (immune, keratin, Melanocyte inducing transcription factor [MITF]-low), and DNA methylation (CpG, hypermethylated, hypomethylated, normal) subtypes (Figures S2A and S2B; Table S1). Projection of chromatin state data using multidimensional scaling (MDS) analysis revealed chromatin state E13 (poised H3K27me3) separated *NRAS* mutant tumors from *BRAF* mutant and WT samples in the first dimension (Figures 1C, 1D, and S2C). Moreover, differential analysis of bivalent chromatin states demonstrated *NRAS* enrichment for poised H3K27me3 domains (Figures 1E, S2D, and S2E). The identification of all potential bivalent combinations revealed a marked increase of bivalent H3K27me3, but not H3K9me3 or H3K27/H3K9me3, in tumor samples, MSTCs, CCLE lines, and isogenic mutant melanocytes harboring an *NRAS*<sup>Q61K</sup> or *BRAF*<sup>V600E</sup> mutation (Fiziev et al., 2017; Garraway et al., 2005; Rai et al., 2015) (Figures 1F–1K and S3A–S3E). In accordance with our chromatin state analysis, *NRAS* mutants displayed the greatest number of bivalent H3K27me3 loci out of all the subgroups, whereas WT samples displayed the least number of bivalent loci on a global and meta-gene level (Figures

1F, 1G, and S3A–S3E). Similarly, *NRAS*<sup>Q61K</sup> isogenic mutants (p*NRAS*) contained increased bivalent H3K27me3-associated loci compared with *BRAF*<sup>V600E</sup> mutants (p*BRAF*) (Figures 1H and 1I). Overlaps of bivalent domains in metastatic (m) m*NRAS* and m*BRAF* mutant tumors to those of isogenic mutants, as well as k-means clustering of H3K4me3 and H3K27me3 across all samples, showed enrichment of bivalent chromatin on both a genome-wide and meta-gene level (Figures 1J and 1K). Finally, we noted substantial overlaps between MSTC bivalent loci with the metastatic m*NRAS* and m*BRAF* mutant groups (Figures S3F and S3G), further demonstrating bivalent chromatin domains are enriched in *NRAS* mutant metastatic melanoma.


### Bivalent domains are lost and gained on key mesenchymal genes

Previous studies have demonstrated various cancer-related genes (i.e., *CDKN2A*) maintain or acquire bivalent promoters in normal tissues (Jadhav et al., 2016); however, their role in melanoma progression has yet to be described. To determine how subtype-specific bivalent H3K27me3 losses and gains influence in melanoma progression, we calculated the overlaps of bivalent sites from m*NRAS* and m*BRAF* mutants to those in isogenic mutant melanocytes (p*NRAS* and p*BRAF*) and primary melanocytes (unmodified) from Roadmap data (Figures 2A and S3H–S3K). We observed a potential shift in bivalent domains as melanocytes progress toward melanoma, with a global decrease of bivalent loci in *BRAF* mutants and a global increase in *NRAS* mutants (Figures 2B and 2C). Average density analysis of these bivalent domains displayed low levels of active transcription marks (H3K27ac and H3K79me2) within these regions, further suggesting these domains are truly bivalent (Figures 2D–2F). We posited that removal of H3K27me3 mark from bivalent loci in melanocytes (“bivalent losses”) would lead to transcriptionally “active” loci in melanoma tumors, whereas gains of H3K27me3 mark on loci (“bivalent gains”) that harbor H3K4me3 in melanocytes (bivalent in tumors) will lead to transcriptional repression (Figure S3L). Determination of the gene targets (within –10 kilobases [kb] of TSSs to transcription end sites [TESs]) and subsequent pathway enrichment of bivalent gains and losses identified critical melanoma-associated “hallmark pathways” within each

### Figure 1. Bivalent H3K27me3 chromatin states are enriched in metastatic melanoma

- (A) Combinatorial chromatin state definitions and histone mark probabilities identified in 20 metastatic melanoma tumor samples using the ChromHMM algorithm.
- (B) Boxplot illustrating mean gene expression levels from RNA-seq based on genomic regions overlapping with each chromatin state.
- (C and D) MDS analysis of chromatin state E13 (poised H3K27me3 high) annotated by mutation (*NRAS*, *BRAF*, WT). (D) RNA expression (immune, keratin, MITF-low) and DNA methylation (normal, CpG, hyper, hypo) classifications from The Cancer Genome Atlas.
- (E) Heatmap displaying differentially regulated regions (false discovery rate [FDR] < 0.05) of chromatin state E13 (poised H3K27me3 high) between *NRAS* and *BRAF* tumor subtypes. p values were calculated using a Wilcoxon test.
- (F) Common bivalent H3K27me3 (H3K4me3 + H3K27me3), bivalent H3K9me3 (H3K4me3 + H3K9me3) and bivalent H3K27/H3K9me3 (H3K4me3 + H3K27me3 + H3K9me3) loci in melanoma tumor subtypes and melanoma short-term cultures (MSTCs) and CCLE lines.
- (G) Co-occupancy analysis of common bivalent associated loci in melanoma tumor subtypes directly overlapping bivalent loci in representative MSTCs or CCLE lines.
- (H) Barplot of H3K4me3 and H3K27me3 associated loci in isogenic mutant melanocytes harboring an *NRAS* (p*NRAS*) or *BRAF* (p*BRAF*) mutation.
- (I) Venn diagram analysis of bivalent loci in p*NRAS* and p*BRAF* isogenic mutant melanocytes.
- (J) Venn diagram analysis of bivalent loci in *NRAS* and *BRAF* mutant melanoma tumors with isogenic mutant melanocytes harboring an *NRAS* or *BRAF* mutation.
- (K) Heatmap of H3K4me3 and H3K27me3 signal at –10 to +10 kb around transcription start sites (TSSs) of all ensemble genes in *NRAS* mutant melanoma tumors (m*NRAS*), *BRAF* mutant melanoma tumors (m*BRAF*), WT melanoma tumors (mWT), MSTCs, CCLE cell lines, and isogenic mutant melanocytes harboring an *NRAS* or *BRAF* mutation.

See also Figures S1–S3 and Table S1.



**Figure 2. Bivalent domains are lost and gained on mesenchymal genes**

(A) Venn diagram analysis of bivalent H3K27me3 loci in mNRAS, mBRAF, and mWT tumor subtypes.

(B and C) Venn diagram analysis of unique bivalent H3K27me3 loci in mNRAS. (C) mBRAF tumor subtypes overlapping bivalent polycomb sites in isogenic mutant melanocytes and primary melanocytes from Roadmap.

(D–F) Average density profiles of H3K4me3, H3K27me3, H3K27ac, and H3K79me3 in mNRAS and mBRAF melanoma tumor subtypes. (E) Isogenic mutant melanocytes and (F) primary melanocytes from Roadmap.

(legend continued on next page)



genetic subgroup (Figure 2G). For example, in *NRAS* mutants, losses of melanocyte-specific bivalency included genes associated with the “EMT” and “KRAS-signaling up,” while gains of tumor-specific bivalency included genes associated with “KRAS-signaling down” and “apical junction” (Figure 2G; Table S2). Apart from known activation of RAS-RAF pathway genes, various studies have demonstrated importance of mesenchymal driver genes in the invasive behavior of metastatic melanoma and other malignancies (Brabletz et al., 2018; Caramel et al., 2013; Kalluri and Weinberg, 2009).

Identification of metastatic drivers that are subjected to bivalent regulation included key EMT-TFs *ZEB1*, *TWIST1*, *SNAI1*, and *CDH1*, which do not harbor genetic changes in melanoma (Figure S3M). On the *TWIST1* and *ZEB1* promoters, we found melanocytes harbor a bivalent configuration similar to that of embryonic stem cells (ESCs), which further switches to a transcriptionally active state upon isogenic mutation and remains active during metastasis (Figures 2H, 2I, S3N, S3O, S4A, and S4B). Genes such as *SNAI1*, however, continue to retain a bivalent configuration upon isogenic mutation and are transcriptionally active only in metastatic samples (Figures S3N and S3O). In contrast to bivalent losses, on genes such as *CDH1* and *CDH3* we found ESCs and melanocytes harbor transcriptionally active H3K4me3 and gain repressive bivalency upon isogenic mutation (Figures 2J, 2K, S4A, and S4B), suggesting EMT-TFs are dynamically regulated during melanoma progression. Importantly, these bivalent switches are significantly correlated with mRNA expression levels in our primary cohort or in a large cohort of metastatic tumors from TCGA. Since bivalent domains in ESCs are known to be functional, allowing either rapid transcriptional activation or progression to stable silencing of gene expression, it is plausible these melanocyte-specific bivalent domains are functionally poised for activation.

#### A subset of melanocyte-specific bivalent genes transition to transcriptionally active broad H3K4me3

In contrast to typical H3K4me3 domains that are usually 200–1,000 bp long, broad H3K4me3 domains can span thousands of kilobases and have been implicated in various cellular processes, including increased gene expression, enhancer activity, and tumor-suppressor gene regulation (Benayoun et al., 2014; Chen et al., 2015; Dahl et al., 2016). Hence, we posited that genes losing bivalency in melanocytes may retain or acquire different signatures (broad or non-broad) of H3K4me3 in melanoma tumors. To this end, we systematically identified broad H3K4me3 domains by computing the overall width and density

from MACS2 broad peaks in melanoma tumors and primary melanocytes (Figures 3A–3D). Globally, m*NRAS* and m*BRAF* mutant subtypes, as well as primary melanocytes, harbored the largest number of broad H3K4me3 peaks, in some cases spanning >30 kb (Figure 3A). We observed the broadest domains extended well beyond that of typical H3K4me3 (200–1,000 bp), with peaks reaching >4 kb in 15 of 17 of the individual samples (m*NRAS* and m*BRAF*) (Figures S4C and S4D). Separation of domains >4 kb to domains <4 kb revealed two distinct types of H3K4me3 in melanoma tumors, including broad domains spanning outside of the transcription start site (TSS) and non-broad domains localized within the promoter region (Figures 3E and S4E). Consistent with previous studies (Chen et al., 2015), we observed other epigenetic marks coincide with H3K4me3 domain width, in which active H3K27ac, H3K4me1, and H3K79me2 had similarly wide peaks at promoters harboring broad H3K4me3 (Figure 3E).

To identify the subsets of melanocyte-specific bivalent genes that transition to transcriptionally active broad domains (and lose H3K27me3 in tumors), we further overlapped genes that harbor (1) bivalent domains uniquely in melanocytes (but not in tumors), (2) tumor-specific broad or non-broad H3K4me3 domains, (3) active transcription mark H3K79me2, and (4) gene expression (using TCGA RNA-seq data [Cancer Genome Atlas Network, 2015; Colaprico et al., 2016] from m*NRAS* [n = 81], m*BRAF* [n = 118], and m*WT* [n = 38] metastatic samples). Integrative analysis revealed m*NRAS*-specific broad domains were associated with increased gene expression (Figures 3F–3I; Table S3) and enriched for melanoma pathways such as “KRAS signaling up,” “UV response up,” and “Glycolysis” (Figure 3J). Genes displaying the transition to transcriptionally active broad H3K4me3 included critical metastatic drivers known to function in the switch to a mesenchymal/invasive state, including *SOX9*, *PDGFA*, *PDGFRA*, and *MYCN* (3.7 kb width) (Figures 3K, 3L, S4F, and S4G), suggesting a role for broad H3K4me3 domains in the regulation of mesenchymal genes in melanoma. In contrast to broad domains, we identified a relatively large and constant number of genes transitioning from a bivalent state to non-broad H3K4me3, many of which were shared in *NRAS* and *BRAF* mutants and associated with increased expression levels (Figures 3F–3I).

#### Broad H3K4me3 domain shortening correlates with transcriptional repression

Our results suggest that during the transition from a bivalent to an active state, a subset of genes that retain broad H3K4me3

(G) Top 5 significant MSigDB/GSEA HALLMARK pathways based on bivalent H3K27me3 loci that are lost and gained within  $\pm 10$  kb TSS-TES of a gene in m*NRAS* and m*BRAF* tumor subtypes.


(H) Genome browser view of ChIP-seq tracks for H3K4me3, H3K27me3, and active transcription (H3K79me2/H3K36me3) on the *TWIST1* and *ZEB1* genes in m*NRAS* and m*BRAF* melanoma tumor subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap.

(I) Boxplot displaying quantile normalized mean RNA expression profiles ( $\log_2$  transcript per million [TPM]) of the *TWIST1* and *ZEB1* genes in melanocytes (n = 2) and melanoma tumor subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and melanoma tumor subtypes (NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. \*p < 0.05; \*\*p < 0.0001.

(J) Genome browser view of ChIP-seq tracks for H3K4me3, H3K27me3, and active transcription (H3K79me2/H3K36me3) on the *CDH3* and *CDH1* genes in m*NRAS* and m*BRAF* melanoma tumor subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap.

(K) Boxplot displaying quantile normalized mean RNA expression profiles ( $\log_2$  TPM) of the *CDH3* and *CDH1* genes in melanocytes (n = 2) and melanoma tumor subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and melanoma tumor subtypes (NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. \*p < 0.05; \*\*p < 0.0001.

See also Figures S3 and S4 and Table S2.



(legend on next page)

domains are associated with increased transcriptional activation; however, this was only observed on a small number of genes (mNRAS = 89 and pNRAS = 45) (Figure 3G). We considered that another mechanism of gene activation could be spreading of the H3K4me3 signal, while gene repression may be associated with shortening of the broad H3K4me3 domains. On a genome-wide level and within gene-associated domains ( $\pm 10$  kb TSS), we observed preferential shortening (<2 kb) of H3K4me3 peaks in melanoma tumors relative to melanocytes (Figures 4A and 4B). The majority of genes that displayed shortening in metastatic tumors were shared with isogenic mutants and associated with a decrease in gene expression levels (Figures 4C–4E; Tables S4 and S5), suggesting broad H3K4me3 shortening is an early event in response to NRAS or BRAF oncogenic activation and a proxy for transcriptional activity. Promoters harboring some of the broadest H3K4me3 domains that displayed marked shortening and decreased gene expression included critical melanocyte-specific cell-identity genes, such as *PMEL* (also known as *GP100*), *PAX3*, *MITF*, and *TFAP2A* (Seberg et al., 2017) (Figures 4F, 4G, and S4H). During developmental progression, this broad H3K4me3 signature was not present in ESCs or germ layer cells (Figures 4H and 4I), indicating these domains are unique to fully differentiated somatic cells. Together, these results identify broad H3K4me3 domains as an epigenetic feature of melanoma progression.

### PRC2 complex regulates aberrant bivalent H3K27me3 domains


Trimethylation of H3K27 through an active PRC2 complex (EZH2, SUZ12, and EED) represses the expression of genes with acquired, tissue-restricted promoter bivalency (Jadhav et al., 2016). To determine whether PRC2 members are aberrantly expressed in metastatic melanoma, we first investigated their gene expression in tumor samples using TCGA RNA-seq data (Cancer Genome Atlas Network, 2015; Colaprico et al., 2016) from mNRAS (n = 81), mBRAF (n = 118), and mWT (n = 38). Here, NRAS mutant melanomas displayed increased expression of *SUZ12* (p value = 0.037) compared with BRAF mutant samples (Figures 5A and S5A), and we further observed an increase of *SUZ12* expression (p value = 0.053) in NRAS

mutant melanoma in tumor dataset GSE15605 (Figures 5B and S5B) (Raskin et al., 2013). Furthermore, immunohistochemistry (IHC) of tissue microarrays (TMAs) harboring stages III and IV melanoma samples with annotated NRAS (patients = 7; samples = 14) and BRAF mutations (patients = 18; samples = 35) and western blotting analysis of MSTCs revealed that NRAS mutant, but not BRAF mutant, melanomas highly express SUZ12 (Figures 5C–5E and S5C–S5E). Consistently, we found that reducing NRAS levels in NRAS mutant MSTC-2125 using two different single guide RNAs (sgRNAs) decreased the expression of SUZ12, but not EZH2 (Figure 5F), further demonstrating an association between NRAS mutants and SUZ12 expression.

We found that bivalent domains in melanoma associate with PRC2 members SUZ12 and EZH2, with 759 domains identified in NRAS mutants and 932 domains in BRAF mutants (Figures 5G and 5H). The majority of PRC2-associated bivalent domains localized within  $\pm 10$  kb of a TSS (96.3% in NRAS mutants and 95.6% in BRAF mutants) (Figure 5I), suggesting these bivalent domains may be functional in regulating target gene expression. To examine the functional role of PRC2 in modulating bivalent H3K27me3-associated loci, we tested the impact of a potent EZH2 inhibitor, GSK-126 (McCabe et al., 2012; Verma et al., 2012), on these domains. As expected, EZH2 inhibition markedly decreased the global and site-specific levels of H3K27me3, as well as bivalent H3K27me3 associated loci, in both NRAS and BRAF mutant melanomas (Figures 5J–5L). The association of bivalent H3K27me3 domains with PRC2 and the disruption of H3K27me3-associated loci through EZH2 inhibition was observed on multiple EMT-TFs and critical developmental genes (Figures S5F–S5H). With these observations, we further postulated that bivalent domains may be functional in regulating the expression of EMT-TF genes in metastatic melanoma. In breast cancer, transforming growth factor  $\beta$  (TGF- $\beta$ ) enables the transition from a bivalent to active state at the *ZEB1* promoter, a process associated with the removal of H3K27me3 (Chaffer et al., 2013). In melanoma, inhibiting H3K27me3 through GSK-126 treatment induced a dose-dependent increase of *ZEB1* mRNA expression levels in multiple cell lines, including Malme-3M, IGR-1, and SK-MEL-28 (Figure 5M). An increase of the *TWIST1* gene was further observed in WM266-4 cells in response to

### Figure 3. A subset of melanocyte-specific bivalent genes transition to transcriptionally active H3K4me3

(A–D) Scatterplots of peak width (x axis) and height (y axis) from MACS2 broad peak calls (p value  $1e-5$ ) for H3K4me3 in mNRAS mutant tumors. (B) mBRAF mutant tumors, (C) mWT tumors, and (D) melanocytes from Roadmap. (E) Heatmap of H3K4me3, H3K27ac, H3K4me1, and H3K79me2 signal at  $-10$  to  $+10$  kb around TSSs of ensemble genes based on H3K4me3 domain width in melanoma tumors. (F) Barplot of bivalent H3K27me3 genes ( $\pm 10$  kb TSS-TES) that are lost in melanocytes and associated with broad or non-broad H3K4me3 in mNRAS, mBRAF, mWT melanoma tumor subtypes, and isogenic mutant melanocytes. (G and H) Venn diagram of broad or non-broad H3K4me3 domains overlapping in mNRAS tumors and pNRAS melanocytes and (H) mBRAF tumors and pBRAF melanocytes. (I) Boxplot displaying quantile normalized mean RNA expression profiles of mNRAS (n = 81) and mBRAF (n = 118) tumor subtypes and melanocytes (n = 86) based on broad or non-broad H3K4me3-associated genes identified in (G) and (H). p values were calculated using a Wilcoxon test. (J) Top significant GSEA HALLMARK pathways based on bivalent H3K27me3 genes ( $\pm 10$  kb TSS-TES) that are lost in melanocytes and associated with broad or non-broad H3K4me3 domains in mNRAS tumor subtypes identified in (G). (K) Genome browser views of ChIP-seq tracks for H3K4me3, H3K27me3, and active transcription (H3K79me2/H3K36me3) on the *SOX9*, *PDGFA*, and *MYCN* genes in mNRAS, mBRAF, mWT melanoma tumor subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap. (L) Boxplot displaying quantile normalized mean RNA expression profiles (log<sub>2</sub> TPM) of the *SOX9*, *PDGFA*, and *MYCN* genes in melanocytes (n = 2) and melanoma tumor subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and melanoma tumor subtypes (NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. \*p < 0.05; \*\*p < 0.0001. See also Figure S4 and Table S3.



(legend on next page)

GSK-126 treatment, and *SNAI1* was activated in Malme-3M cells, albeit this did not occur in a dose-dependent manner even at lower concentrations (Figure 5N). A dose-dependent increase of ZEB1 protein levels and an increase of SNAI1 protein levels were further observed in Malme-3M cells in response to GSK-126 treatment (Figure S5I). Consistently, we observed a loss or marked decrease of H3K27me3 on the *ZEB1*, *TWIST1*, *SNAI1*, *SOX9*, *TGFBI*, and *PDGFRA* promoters upon EZH2 inhibition (Figures 5O and S5F–S5H). With the ability of EZH2 inhibition to disrupt H3K27me3 on multiple EMT-TF genes harboring a bivalent domain, these data suggest genes involved in the switch to an invasive state may be regulated by shifts of bivalent chromatin in melanoma.

### EZH2 and MEK combination therapy specifically abrogates tumor growth in *NRAS* mutant melanoma

Next, we sought to test the functional and therapeutic implications of our observations on PRC2-mediated increase in bivalent H3K27me3 levels in *NRAS* mutant melanomas. We first tested whether disruption of the PRC2 complex through EZH2 inhibition influenced the proliferative or invasive properties in *NRAS* mutant MSTC cells. While GSK-126 treatment (at 1, 2, and 3  $\mu$ M) did not have a significant effect on cellular proliferation (Figures 6A and 6B), we observed a decrease in the invasive capacity of *NRAS* mutant cell lines (MSTC-2125 and MSTC-2770), but not in *BRAF* mutant cell lines (MSTC-2549 and MSTC-2765) (Figures 6C–6F). As expected, we observed loss in the global levels of H3K27me3 in both subtypes (Figures 5J, S6A, and S6B). Consistent with GSK-126 results, treatment of *NRAS* mutant cell lines with an additional EZH2 inhibitor, 3-deazaneplanocin A (DZNep) (Miranda et al., 2009), induced a global loss of H3K27me3 levels and a decrease in their invasive capacity (Figures S6C–S6E). This is consistent with the effects of bivalent domain reprogramming on mesenchymal driver genes. Since EZH2 inhibition abrogated invasion, but not proliferation, we tested whether EZH2 inhibitors could be combined with proliferation blocking US Food and Drug Administration (FDA)-approved MEK inhibitors to block tumor growth in melanoma. We treated tumors derived from two *NRAS* mutant cultures (MSTC-2125 and MSTC-2770) or *BRAF* mutant cultures (MSTC-2765 and MSTC-2549) in NUDE mice

(n = 5 per condition) with EZH2 inhibitor GSK-126 (150 mg/kg), MEK inhibitor (1 mg/kg), or a combination of EZH2 plus MEK inhibitors. While monotherapy EZH2i or MEKi only showed modest effects, the combination treatment of EZH2i and MEKi drastically reduced the tumor burden of *NRAS* mutant melanoma cells (Figures 6G and 6H). By contrast, we did not observe a combinatorial effect of EZH2i plus MEKi on tumor volumes in *BRAF* mutant melanomas (Figures 6I and 6J). All of these treatments had minimal effects on the body weights of the treated mice (Figure S6F), demonstrating low toxicity from these combinatorial treatments. Importantly, we observed a significant decrease on tumor volume in *BRAF* mutants using *BRAF*<sup>V600E</sup> inhibitor vemurafenib (Figure S6G), demonstrating these samples are not inherently resistant to traditional therapies.

To determine whether EZH2 inhibition impacts invasion, we first checked the lung, liver, and lymph nodes for any nodules from all the mice that were injected with the EZH2 inhibitor or vehicle control in MSTC-2125 tumors. Here, we did not find any evidence for discernible micro or macro metastatic growth in distant organs potentially due to the duration of the experiment. To determine whether EZH2 inhibition impacts invasion on a molecular level, we further evaluated the protein levels of invasive marker vimentin using IHC in vehicle, EZH2, MEK, or EZH2i + MEKi-treated tumors. Interestingly, we observed a significant decrease in the number of vimentin-positive cells upon treatment with EZH2i or EZH2 + MEKi compared with vehicle control (Figures S6H and S6I), together suggesting that while we didn't observe any metastatic events at this time frame, the molecular events promoting invasion and metastasis are impacted by EZH2 inhibition. Together, these results suggest inhibition of PRC2 in combination with MEKi may be a promising therapeutic strategy for *NRAS* mutant melanoma patients that harbor increased PRC2 activity and bivalent H3K27me3 domains.

## DISCUSSION

Using combinatorial chromatin state profiling coupled with mutation, gene expression, and DNA methylation data, we find that a network of genes encompassing EMT-TF and melanocyte-specific cell-identity genes may be regulated by bivalent

### Figure 4. Broad H3K4me3 domain shortening correlates with transcriptional repression

(A) Kernel density estimation plot displaying H3K4me3 peak length change ( $\pm 2$  kb) from melanocytes to melanoma tumor subtypes. Number denotes mean length change in kilobases between melanocytes and melanoma subtype. Asterisk denotes p value  $< 1e-50$  between melanoma subtype length changes.

(B) Barplot of broad H3K4me3 promoter associated sites ( $-10$  to  $+10$  kb) displaying shortening or lengthening ( $\pm 2$  kb) in m*NRAS*, m*BRAF*, and m*WT* melanoma tumor subtypes and isogenic mutant melanocytes relative to primary melanocytes from Roadmap.

(C and D) Venn diagram analysis of broad H3K4me3 domains shortening ( $\pm 2$  kb) relative to melanocytes in m*NRAS* and p*NRAS* and (D) m*BRAF* and p*BRAF* samples.


(E) Boxplot displaying quantile normalized mean RNA-seq expression profiles from m*NRAS* (n = 81) and m*BRAF* (n = 118) melanoma tumor subtypes and melanocytes (n = 86) based on genes displaying shortening ( $\pm 2$  kb) of broad H3K4me3 domains identified in (C) and (D). p values were calculated using a Wilcoxon test.

(F) Genome browser view of ChIP-seq tracks displaying H3K4me3 on the *PMEL*, *PAX3*, *MITF*, and *TFAP2A* genes in m*NRAS*, m*BRAF*, and m*WT* melanoma tumor subtypes, isogenic mutant melanocytes, and primary melanocytes from Roadmap.

(G) Boxplot displaying quantile normalized mean RNA expression profiles (log<sub>2</sub> TPM) of the *PMEL*, *PAX3*, *MITF*, and *TFAP2A* genes in melanocytes (n = 2) and melanoma tumor subtypes (NRAS = 4, BRAF = 13, WT = 3) with associated chromatin profiles (top) and in a large cohort of melanocytes (n = 86) and melanoma tumor subtypes (NRAS = 81, BRAF = 118, WT = 38 [bottom]). p values were calculated using a Wilcoxon test. \*p < 0.05; \*\*p < 0.0001.

(H) Genome browser view of ChIP-seq tracks for H3K4me3, on the *PMEL*, *PAX3*, *MITF*, and *TFAP2A* genes in ESC, trophoblast, mesendoderm, mesoderm, mesenchymal stem cells, endoderm, ectoderm, melanocytes from Roadmap and TCGA tumors, MSTCs, and CCLE cell lines.

(I) Boxplots displaying quantile normalized mean RNA expression profiles (log<sub>2</sub> TPM) of the *PMEL*, *PAX3*, *MITF*, and *TFAP2A* genes in ESC, trophoblast, mesendoderm, mesoderm, mesenchymal stem cells, endoderm, ectoderm, melanocytes from Roadmap and TCGA tumors, MSTCs, and CCLE cell lines. See also Figure S4 and Tables S4 and S5.



(legend on next page)

H3K27me3 and broad H3K4me3 domains in metastatic melanoma. Together, our work provides insight toward four important conceptual advances regarding the role of the epigenome in melanoma and its therapeutic implications (Figure 6K). (1) Genetic events such as *NRAS* or *BRAF* mutations may utilize specific chromatin states to bring about transcriptional changes unique to that genotype. (2) Chromatin state switches involving bivalent H3K27me3 domains occur on critical mesenchymal genes associated with a metastatic phenotype, including the EMT. (3) Exceptionally wide H3K4me3 domains spanning tens of kilobases associate with pro-metastatic drivers and melanocyte-specific cell-identity genes, suggesting roles for this epigenetic element in melanoma. (4) Blocking invasive ability of melanoma via EZH2 inhibitors along with proliferative features using MEK inhibitors may be a key therapeutic principle in *NRAS* mutant melanomas. Overall, the current study encompasses the most comprehensive dataset from a large number of well-annotated samples that is useful for identifying principles of epigenome regulation in melanoma metastasis and suggestions of epigenetic therapies.

Bivalent chromatin domains have primarily been described in ESCs, in which they control the expression of critical lineage-specific genes that gain or lose these modifications as cells differentiate toward a particular phenotype (Bernstein et al., 2006; Voigt et al., 2013). In normal cells, bivalent marks are also found at genes with roles specific to the development of those tissues. Hence, is it plausible these genes were active during organogenesis and an aberrant TF or epigenetic modification can leave them vulnerable to transcription in adult cells. In the context of melanocyte development, migratory neural crest cells undergo an initial EMT to break away from the neural fold and move to distant regions of the embryo (Baker et al., 1997; Sinnberg et al., 2018). This cellular plasticity, or phenotype switching, allows melanocytes to emerge amidst a myriad of other signaling pathways by quickly activating and repressing key regulatory genes, including EMT-TFs. In mel-

noma, the concept of phenotype switching (proliferative to invasive) has been reported, and various EMT-TFs are critical for this process (Caramel et al., 2013; Goding, 2000; Li et al., 2015). Although melanocytes are not part of the epithelial lineage, upon activation of *BRAF* or *NRAS* oncogenes, the EMT-TF network undergoes a reorganization that is associated with the upregulation of *ZEB1* and *TWIST1*, the loss of *CDH1*, increased invasion, and poor prognosis in melanoma patients (Caramel et al., 2013).

In this study, we observed bivalent H3K27me3 domains display dynamic changes and associated gene expression patterns on core members of the EMT-TF network (*ZEB1*, *TWIST1*, *SNAI1*, *TGFB1*, *CDH3*, and *CDH1*) during the transition from ESCs > melanocytes > isogenic mutant melanocytes > metastatic melanoma. All of the core EMT-TF genes identified (with the exception of *SNAI1*) display losses and gains of bivalent H3K27me3 upon isogenic activation of *NRAS* and *BRAF*, indicating this switch occurs early in response to mitogen-activated protein kinase (MAPK) misregulation, and these genes remain active during metastasis. In addition to EMT-TFs, integration of melanocyte-specific bivalent genes that transition to transcriptionally active H3K4me3 domains (and lose H3K27me3 in tumors) revealed *NRAS* mutant-associated broad domains (>4 kb) were enriched on genes critical for neural crest migration and the switch to an invasive state (*SOX9*, *POU3F2*, *MYCN*, *PDGFRA*, and *PDGFA*) (Caramel et al., 2013; Cheng et al., 2015; Li et al., 2015; Simmons et al., 2017; Theveneau and Mayor, 2012), further indicating that melanoma tumor progression may resemble a reactivated developmental program mediated by bivalent switches. Since metastasis involves several cell-fate transitions during its progression from the primary site to colonization, which likely use a transcriptional circuitry consisting of different proliferative or invasive genes, it is plausible shifts involving bivalent chromatin states could be favored as the preferred mode of gene regulation for EMT-TFs during the switch to a metastatic phenotype.

### Figure 5. The PRC2 complex regulates aberrant bivalent H3K27me3 domains

(A) Boxplot displaying quantile normalized mean RNA expression profiles (log<sub>2</sub> TPM) for the *SUZ12* gene in melanoma tumor subtypes (*NRAS* = 81, *BRAF* = 118, WT = 38) from the TCGA dataset.

(B) Boxplot displaying microarray profiles (log<sub>2</sub>) for the *SUZ12* gene in melanoma tumor subtypes (normal skin = 16, *NRAS* = 8, *BRAF* = 28, WT = 22) from the GSE15605 dataset.

(C) Boxplot displaying H-Scores from *SUZ12* immunohistochemistry staining in patient TMA harboring an *NRAS* mutation (patients = 7; samples = 14) or *BRAF* mutation (patients = 18; samples = 35). p values were calculated using a t test based on H-Scores in each mutational subtype.

(D and E) Western blotting analysis and (E) quantification for *SUZ12* and *EZH2* in MSTC harboring an *NRAS* or *BRAF* mutation. Relative density was quantified using ImageJ software, and the values of the target proteins were normalized to b-Actin. The results are representative of three independent biological replicates. Error bars represent mean ± SEM. *NRAS* and *BRAF* mutant MSTCs were run on the same gel and cropped for publication as two additional non-MSTCs were run together.

(F) Western blotting analysis for *NRAS*, *SUZ12*, *EZH2*, and b-Actin in *NRAS* mutant MSTC-2125 expressing scrambled or two different sgRNAs targeting the *NRAS* gene.

(G and H) Venn diagram analysis of bivalent H3K27me3-associated loci in *NRAS* mutant and (H) *BRAF* mutant melanoma samples overlapping with PRC2 complex members *SUZ12* and *EZH2* in ESCs.

(I) Genomic localization of bivalent H3K27me3 + PRC2 complex associated loci.

(J) Western blotting analysis for H3K27me3 in MSTC harboring an *NRAS* mutation treated for 14 days with GSK-126 or DMSO.

(K) Barplot displaying total number of H3K4me3 and H3K27me3 associated loci in Malme-3M cells treated for 14 days with GSK-126 or DMSO.


(L) Venn diagram analysis of bivalent H3K27me3-associated loci in Malme-3M cells treated for 14 days with GSK-126 or DMSO.

(M) qRT-PCR for *ZEB1* in Malme-3M, IGR-1, and SK-MEL-28 cell lines treated for 14 days with GSK-126 or DMSO. p values were calculated using a t test.

(N) qRT-PCR for *TWIST1* WM2664 cell lines and *SNAI1* in Malme-3M cell lines treated for 14 days with GSK-126 or DMSO. p values were calculated using a t test.

(O) Genome browser view of ChIP-seq tracks for *SUZ12*, *EZH2*, H3K4me3, and H3K27me3 in ESCs; H3K4me3 and H3K27me3 in melanocytes; m*NRAS* and m*BRAF* tumors; representative *NRAS* mutant MSTCs (MSTC-2125, MSTC-2770, MSTC-2495); and *BRAF* mutant MSTCs (MSTC-2549, MSTC-2765, MSTC-2357); and in Malme-3M cells treated for 14 days with GSK-126 or DMSO on the *ZEB1*, *TWIST1*, *SNAI1*, and *SOX9* genes.

See also Figure S5.



(legend on next page)



In contrast to genes that lose bivalency and retain H3K4me3, the majority of broad H3K4me3 domains (>4 kb) displayed marked shortening in metastatic melanoma tumors relative to melanocytes. A similar observation in *NRAS* and *BRAF* isogenic mutant melanocytes suggests this is an early event in response to MAPK activation. However, unlike bivalent H3K27me3 domains, broad H3K4me3 shortening was not associated with a specific mutational subtype (*NRAS* or *BRAF*). Previous studies have demonstrated broad H3K4me3 domains are associated with increased gene expression and tumor-suppressor gene regulation (Benayoun et al., 2014; Chen et al., 2015; Dahl et al., 2016). Broad domains that are conserved across normal cells may mark a set of pan-cancer tumor suppressors, whereas cell-type-specific broad H3K4me3 peaks are associated with cell-identity genes (Chen et al., 2015). In melanoma, we found that promoters harboring some of the broadest H3K4me3 domains were associated with melanocyte cell-identity genes known to be downregulated during the switch to an invasive state, including *PMEL* (aka *GP100*), *PAX3*, *MITF*, and *TFAP2A* (Denecker et al., 2014; Goding, 2000; Kemper et al., 2014; Levy et al., 2006; Li et al., 2015; Seberg et al., 2017). The broad H3K4me3 signature was not present in ESCs or germ cells, but instead specifically gained in melanocytes (with the exception of *PAX3* in ectodermal cells), suggesting broad H3K4me3 domains mark cell-identity genes necessary for normal melanocyte function that are lost during oncogenic activation. Importantly, further investigation is needed to determine whether histone methyltransferases responsible for regulating the broad H3K4me3 signal, such as *KMT2D* in medulloblastoma (Dhar et al., 2018), are functional in melanoma and can be targeted therapeutically.

Mechanisms governing bivalent promoters include histone methyltransferases such as PRC2 (EZH2, SUZ12, and EED) (Ku et al., 2008; Voigt et al., 2013). Studies in normal cells suggest tissue-specific mechanisms recruit PRC2 to place H3K27me3 at genes in order to avoid unwanted mRNA expression (Jadhav et al., 2016). In melanoma tumors, EZH2 and H3K27me3 are predominantly expressed at the invasion front and have been linked to an invasive, EMT-associated phenotype (Hoffmann et al., 2020; Shields et al., 2017; Zingg et al., 2017). In this study, we observed *NRAS* mutant melanomas (a highly metastatic and aggressive phenotype [Devitt et al., 2011; Jakob

et al., 2012; Thumar et al., 2014]) harbor increased bivalent H3K27me3 domains and highly express core PRC2 members SUZ12 and EZH2. The high co-localization of bivalent H3K27me3 with SUZ12 and EZH2 on multiple EMT-TF genes suggests these domains may represent functional chromatin elements. Indeed, the ability to active the expression of EMT-TFs by modulating bivalent chromatin structure using EZH2 inhibitors demonstrates some of these domains are functional in cancer. Importantly however, further investigation is needed to determine what other active modifications or TFs regulate these genes, and whether their activation through bivalent modulation can drive an invasive phenotype.

Recently, epigenetic drugs targeting EZH2 have been successfully applied in various preclinical models and are rapidly progressing into clinical trials. For example, a recent clinical trial in patients with urothelial cancer demonstrated synergistic effect of EZH2 treatment and anti-PD1 therapy (NCT03854474). In melanoma cells, inhibition of EZH2 activity affects their invasive capacity and counteracts tumor growth and metastatic spread *in vivo* (Zingg et al., 2015). Here, we found that EZH2 inhibition (GSK-126) decreased H3K27me3 expression, reduced the invasive capacity, and markedly inhibited tumor burden specifically in *NRAS* mutant melanoma cultures, but not *BRAF* mutant cultures, in combination with MEK inhibitor. MEK inhibitor is an FDA-approved therapy in metastatic melanoma and remains a prominent therapy in *NRAS* mutant patients (Boespflug et al., 2017). However, the responses are limited in majority of the treated patients (Devitt et al., 2011; Hoffmann et al., 2020; Jakob et al., 2012; Thumar et al., 2014). Our data suggest that inhibition of proliferation by MEKi (Johnson and Sosman, 2013; Zipser et al., 2011) along with inhibition of the invasive/mesenchymal phenotype by EZH2i could be the biological explanation for the observed effect of combinatorial therapy in *NRAS* mutant melanoma. Thus, these observations provide a conceptual advance for design of future therapeutics to focus on targeting these two processes in *NRAS* mutant melanomas.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

### Figure 6. EZH2i and MEKi combination therapy decreases tumor burden in *NRAS* mutant melanoma

(A and B) Proliferation assay representing confluence percentage in *NRAS* mutant MSTC cell lines 2125 and (B) 2770 treated for 14 days with GSK-126 or DMSO. Error bars represent mean  $\pm$  SEM.

(C and D) Boyden chamber invasion assay in *NRAS* mutant MSTC cell lines 2125 and (D) 2770 treated for 14 days with GSK-126 or DMSO. p values were calculated using a t test. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001. Error bars represent mean  $\pm$  SEM.

(E and F) Boyden chamber invasion assay in *BRAF* mutant MSTC cell lines 2549 and (F) 2765 treated for 14 days with GSK-126 or DMSO. p values were calculated using a t test. \*p < 0.05. Error bars represent mean  $\pm$  SEM.

(G–J) Tumor volume curves for *NRAS* mutant melanoma cultures (G) MSTC-2125 and (H) MTSC-2770 or *BRAF* mutant melanoma cultures (I) MSTC-2549 and (J) MSTC-2765, upon treatment with vehicle, MEK inhibitors (trametinib), EZH2 inhibitor (GSK-126), and a combination of MEK and EZH2 inhibitors (trametinib + GSK-126) (n = 5 for each arm). p values represent pairwise t test comparison between the experimental arm to vehicle treatment. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001. Error bars represent mean  $\pm$  SEM.

(K) Model explaining potential mechanism in which switches of bivalent H3K27me3 domains on EMT-TFs, and shortening of H3K4me3 domains on melanocyte-specific cell-identity genes, control their expression during the switch from a proliferative to an invasive phenotype in metastatic melanoma. EMT-TFs and melanocyte-specific genes identified here are differentially expressed in alternate phenotypic states, with *ZEB1*, *TWIST1*, *SNAI1*, *SOX9*, *PDGFRA*, and *PDGFA* displaying high expression in a mesenchymal/invasive phenotype and *CDH1*, *MITF*, *PAX3*, *PMEL*, and *TFAP2A* displaying high expression in melanocytes/proliferative phenotype.

See also Figure S6.

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Human subjects
  - Animals
  - Cell lines
  - Isogenic mutant melanocytes
- METHOD DETAILS
  - Chromatin immunoprecipitation assays
  - ChIP-seq data processing
  - Chromatin state analysis
  - Correlation of copy number from ChIP-seq and SNP array
  - Correlation of RNA expression and chromatin state data
  - Correlation of DNA methylation and chromatin state data
  - Identification and visualization of ChIP-seq associated loci
  - Identification of broad H3K4me3 domains
  - Assigning associated loci to genes
  - Gene set enrichment analysis
  - RNA-sequencing data processing
  - Proliferation assays
  - Boyden Chamber invasion assays
  - Immunoblot analysis
  - Acid extraction of histones
  - Stable cell line generation
  - Quantitative PCR
  - Immunohistochemistry for patient tissue microarrays
  - Immunohistochemistry for murine tumor samples
  - *In vivo* assays
- QUANTIFICATION AND STATISTICAL ANALYSIS

#### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2021.109410>.

#### ACKNOWLEDGMENTS

We are grateful to Kadir C. Akdemir, Yonathan Lissanu Deribe, Anand Singh, Scott Callahan, Veena Kochat, Sharon Landers, Angela Bhalla, and Keila Torres for helpful discussions and proofreading the manuscript. The work described in this article was supported by grants from the National Institutes of Health (CA160578 to K.R.; CA016672 to SMF Core), Center for Cancer Epigenetics at MDACC (to C.J.T. and K.R.), and MD Anderson Cancer Center (start-up funds to K.R.). Short tandem repeat (STR) DNA fingerprinting was done by the UTMDACC CCSG-funded Characterized Cell Line Core, NCI CA016672. The molecular characterization of the short-term culture tumor lines was supported by generous philanthropic contributions to The University of Texas MD Anderson Moon Shots Program.

#### AUTHOR CONTRIBUTIONS

C.J.T. and K.R. conceptualized and designed the study. C.J.T. and M.M. generated ChIP-seq data. C.J.T., M.T., M.M., and S.A. processed ChIP-seq data. C.J.T., M.T., A.R., and J.S. performed data analysis for ChIP-seq.

C.J.T., M.T., and A.T.R. processed and performed data analysis for RNA-seq. K.R. performed *in vivo* experiments. C.J.T. performed proliferation and invasion assays. M.M. quantified proliferation assays. K.R. and C.J.T. quantified invasion assays. A.K.G. and C.J.T. performed and quantified western blotting analysis. C.J.T. generated CRISPR-Cas9 cell lines. C.J.T. performed dose-dependent qRT-PCR assays. M.M. performed IHC for *in vivo* mouse tissues. P.B. performed IHC imaging for *in vivo* mouse tissues. S.K., R.L., and K.W. performed IHC for patient TMAs. J.O., C.C., C.J.W., C.B., and S.E.W. generated and characterized the STCs. E.O., A.S., S.S., K.T., D.Z., and K.C. provided intellectual input. C.J.T. and K.R. wrote and prepared the manuscript. All authors read and approved the manuscript.

#### DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: June 4, 2020

Revised: May 13, 2021

Accepted: June 25, 2021

Published: July 20, 2021

#### REFERENCES

- Baker, C.V., Bronner-Fraser, M., Le Douarin, N.M., and Teillet, M.A. (1997). Early- and late-migrating cranial neural crest cell populations have equivalent developmental potential *in vivo*. *Development* **124**, 3077–3087.
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* **483**, 603–607.
- Benayoun, B.A., Pollina, E.A., Ucar, D., Mahmoudi, S., Karra, K., Wong, E.D., Devarajan, K., Daugherty, A.C., Kundaje, A.B., Mancini, E., et al. (2014). H3K4me3 breadth is linked to cell identity and transcriptional consistency. *Cell* **158**, 673–688.
- Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell* **125**, 315–326.
- Besser, M.J., Shapira-Frommer, R., Treves, A.J., Zippel, D., Itzhaki, O., Schallmach, E., Kubi, A., Shalmon, B., Hardan, I., Catane, R., et al. (2009). Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. *J. Immunother.* **32**, 415–423.
- Boespflug, A., Caramel, J., Dalle, S., and Thomas, L. (2017). Treatment of *NRAS*-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date. *Ther. Adv. Med. Oncol.* **9**, 481–492.
- Brabletz, T., Kalluri, R., Nieto, M.A., and Weinberg, R.A. (2018). EMT in cancer. *Nat. Rev. Cancer* **18**, 128–134.
- Cancer Genome Atlas Network (2015). Genomic Classification of Cutaneous Melanoma. *Cell* **161**, 1681–1696.
- Caramel, J., Papadogeorgakis, E., Hill, L., Browne, G.J., Richard, G., Wierincx, A., Saldanha, G., Osborne, J., Hutchinson, P., Tse, G., et al. (2013). A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. *Cancer Cell* **24**, 466–480.
- Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabetot, T.S., Salama, S.R., Murray, B.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., et al. (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell* **164**, 550–563.
- Chaffer, C.L., Marjanovic, N.D., Lee, T., Bell, G., Kleer, C.G., Reinhardt, F., D'Alessio, A.C., Young, R.A., and Weinberg, R.A. (2013). Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. *Cell* **154**, 61–74.
- Chen, K., Chen, Z., Wu, D., Zhang, L., Lin, X., Su, J., Rodriguez, B., Xi, Y., Xia, Z., Chen, X., et al. (2015). Broad H3K4me3 is associated with increased

- transcription elongation and enhancer activity at tumor-suppressor genes. *Nat. Genet.* **47**, 1149–1157.
- Cheng, P.F., Shakhova, O., Widmer, D.S., Eichhoff, O.M., Zingg, D., Frommel, S.C., Belloni, B., Raaijmakers, M.I., Goldinger, S.M., Santoro, R., et al. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. *Genome Biol.* **16**, 42.
- Colaprico, A., Silva, T.C., Olsen, C., Garofano, L., Cava, C., Garolini, D., Sabetdot, T.S., Malta, T.M., Pagnotta, S.M., Castiglioni, I., et al. (2016). TCGAAbioLinks: an R/Bioconductor package for integrative analysis of TCGA data. *Nucleic Acids Res.* **44**, e71.
- Corces, M.R., Granja, J.M., Shams, S., Louie, B.H., Seoane, J.A., Zhou, W., Silva, T.C., Groeneveld, C., Wong, C.K., Cho, S.W., et al. (2018). The chromatin accessibility landscape of primary human cancers. *Science* **362**, eaav1898.
- Dahl, J.A., Jung, I., Aanes, H., Greggains, G.D., Manaf, A., Lerdrup, M., Li, G., Kuan, S., Li, B., Lee, A.Y., et al. (2016). Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition. *Nature* **537**, 548–552.
- Dambacher, S., Hahn, M., and Schotta, G. (2010). Epigenetic regulation of development by histone lysine methylation. *Heredity* **105**, 24–37.
- Denecker, G., Vandamme, N., Akay, O., Koludrovic, D., Taminau, J., Lemeire, K., Gheldof, A., De Craene, B., Van Gele, M., Brochez, L., et al. (2014). Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. *Cell Death Differ.* **21**, 1250–1261.
- Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C.Y., Dobrovic, A., and McArthur, G. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. *Pigment Cell Melanoma Res.* **24**, 666–672.
- Dhar, S.S., Zhao, D., Lin, T., Gu, B., Pal, K., Wu, S.J., Alam, H., Lv, J., Yun, K., Gopalakrishnan, V., et al. (2018). MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. *Mol. Cell* **70**, 825–841.e6.
- Ekmekcioglu, S., Davies, M.A., Tanese, K., Roszik, J., Shin-Sim, M., Bassett, R.L., Jr., Milton, D.R., Woodman, S.E., Prieto, V.G., Gershenwald, J.E., et al. (2016). Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. *Clin. Cancer Res.* **22**, 3016–3024.
- ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74.
- Ernst, J., and Kellis, M. (2012). ChromHMM: automating chromatin-state discovery and characterization. *Nat. Methods* **9**, 215–216.
- Faust, G.G., and Hall, I.M. (2014). SAMBLASTER: fast duplicate marking and structural variant read extraction. *Bioinformatics* **30**, 2503–2505.
- Fiziev, P., Akdemir, K.C., Miller, J.P., Keung, E.Z., Samant, N.S., Sharma, S., Natale, C.A., Terranova, C.J., Maitiuheti, M., Amin, S.B., et al. (2017). Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. *Cell Rep.* **19**, 875–889.
- Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., Beroukhi, R., Milner, D.A., Grant, S.R., Du, J., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature* **436**, 117–122.
- Goding, C.R. (2000). Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. *Genes Dev.* **14**, 1712–1728.
- Hodis, E., Watson, I.R., Kryukov, G.V., Arold, S.T., Imielinski, M., Theurillat, J.P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012). A landscape of driver mutations in melanoma. *Cell* **150**, 251–263.
- Hoffmann, F., Niebel, D., Aymans, P., Ferring-Schmitt, S., Dietrich, D., and Landsberg, J. (2020). H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade. *Clin. Epigenetics* **12**, 24.
- Iida, Y., Ciechanover, A., Marzese, D.M., Hata, K., Bustos, M., Ono, S., Wang, J., Salomon, M.P., Tran, K., Lam, S., et al. (2017). Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF- $\kappa$ B Pathway in Melanoma. *Clin. Cancer Res.* **23**, 4831–4842.
- Jadhav, U., Nalapareddy, K., Saxena, M., O'Neill, N.K., Pinello, L., Yuan, G.C., Orkin, S.H., and Shivdasani, R.A. (2016). Acquired Tissue-Specific Promoter Bivalency Is a Basis for PRC2 Necessity in Adult Cells. *Cell* **165**, 1389–1400.
- Jakob, J.A., Bassett, R.L., Jr., Ng, C.S., Curry, J.L., Joseph, R.W., Alvarado, G.C., Rohlf, M.L., Richard, J., Gershenwald, J.E., Kim, K.B., et al. (2012). NRAS mutation status is an independent prognostic factor in metastatic melanoma. *Cancer* **118**, 4014–4023.
- Janes, K.A. (2015). An analysis of critical factors for quantitative immunoblotting. *Sci. Signal.* **8**, rs2.
- Johnson, D.B., and Sosman, J.A. (2013). Update on the targeted therapy of melanoma. *Curr. Treat. Options Oncol.* **14**, 280–292.
- Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial-mesenchymal transition. *J. Clin. Invest.* **119**, 1420–1428.
- Kapoor, A., Goldberg, M.S., Cumberland, L.K., Ratnakumar, K., Segura, M.F., Emanuel, P.O., Menendez, S., Vardabasso, C., Leroy, G., Vidal, C.I., et al. (2010). The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. *Nature* **468**, 1105–1109.
- Kemper, K., de Goeje, P.L., Peeper, D.S., and van Amerongen, R. (2014). Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. *Cancer Res.* **74**, 5937–5941.
- Ku, M., Koche, R.P., Rheinbay, E., Mendenhall, E.M., Endoh, M., Mikkelsen, T.S., Presser, A., Nusbaum, C., Xie, X., Chi, A.S., et al. (2008). Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. *PLoS Genet.* **4**, e1000242.
- Kuilman, T., Velds, A., Kemper, K., Ranzani, M., Bombardelli, L., Hoogstraat, M., Nevedomskaya, E., Xu, G., de Ruyter, J., Lolkema, M.P., et al. (2015). Copywriter: DNA copy number detection from off-target sequence data. *Genome Biol.* **16**, 49.
- Kundaje, A., Meuleman, W., Ernst, J., Bilenyk, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al. (2015). Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330.
- Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25.
- Lens, M.B., and Dawes, M. (2004). Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. *Br. J. Dermatol.* **150**, 179–185.
- Levy, C., Khaled, M., and Fisher, D.E. (2006). MITF: master regulator of melanocyte development and melanoma oncogene. *Trends Mol. Med.* **12**, 406–414.
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079.
- Li, F.Z., Dhilon, A.S., Anderson, R.L., McArthur, G., and Ferrao, P.T. (2015). Phenotype switching in melanoma: implications for progression and therapy. *Front. Oncol.* **5**, 31.
- Lin, C.Y., Erkek, S., Tong, Y., Yin, L., Federation, A.J., Zaparka, M., Haldipur, P., Kawachi, D., Risch, T., Warnatz, H.J., et al. (2016). Active medulloblastoma enhancers reveal subgroup-specific cellular origins. *Nature* **530**, 57–62.
- Liu, T., Ortiz, J.A., Taing, L., Meyer, C.A., Lee, B., Zhang, Y., Shin, H., Wong, S.S., Ma, J., Lei, Y., et al. (2011). Cistrome: an integrative platform for transcriptional regulation studies. *Genome Biol.* **12**, R83.
- Lomber, G., Blum, Y., Nicolle, R., Nair, A., Gaonkar, K.S., Marisa, L., Mathison, A., Sun, Z., Yan, H., Elarouci, N., et al. (2018). Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. *Nat. Commun.* **9**, 1978.
- McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S., Liu, Y., Graves, A.P., Della Pietra, A., 3rd, Diaz, E., et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* **492**, 108–112.
- Miller, A.J., and Mihm, M.C., Jr. (2006). Melanoma. *N. Engl. J. Med.* **355**, 51–65.

- Miranda, T.B., Cortez, C.C., Yoo, C.B., Liang, G., Abe, M., Kelly, T.K., Marquez, V.E., and Jones, P.A. (2009). DNase is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. *Mol. Cancer Ther.* **8**, 1579–1588.
- Neph, S., Kuehn, M.S., Reynolds, A.P., Haugen, E., Thurman, R.E., Johnson, A.K., Rynes, E., Maurano, M.T., Vierstra, J., Thomas, S., et al. (2012). BEDOPS: high-performance genomic feature operations. *Bioinformatics* **28**, 1919–1920.
- Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Beriman, B.P., Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* **17**, 510–522.
- Oba, J., Kim, S.H., Wang, W.L., Macedo, M.P., Carapeto, F., McKean, M.A., Van Arnam, J., Eterovic, A.K., Sen, S., Kale, C.R., et al. (2018). Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in *KIT*-Mutant Melanoma. *JCO Precis. Oncol.* **2018**, PO.18.00055.
- Ortega-Molina, A., Boss, I.W., Canela, A., Pan, H., Jiang, Y., Zhao, C., Jiang, M., Hu, D., Agirre, X., Niesvizky, I., et al. (2015). The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. *Nat. Med.* **21**, 1199–1208.
- Park, J., Talukder, A.H., Lim, S.A., Kim, K., Pan, K., Melendez, B., Bradley, S.D., Jackson, K.R., Khalil, J.S., Wang, J., et al. (2017). SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. *Cancer Immunol. Res.* **5**, 618–629.
- Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842.
- Rai, K., Akdemir, K.C., Kwong, L.N., Fiziev, P., Wu, C.J., Keung, E.Z., Sharma, S., Samant, N.S., Williams, M., Axelrad, J.B., et al. (2015). Dual Roles of RNF2 in Melanoma Progression. *Cancer Discov.* **5**, 1314–1327.
- Ramírez, F., Ryan, D., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A.S., Heyne, S., Dündar, F., and Manke, T. (2016). deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* **44**, W160–W165.
- Raskin, L., Fullen, D.R., Giordano, T.J., Thomas, D.G., Frohm, M.L., Cha, K.B., Ahn, J., Mukherjee, B., Johnson, T.M., and Gruber, S.B. (2013). Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. *J. Invest. Dermatol.* **133**, 2585–2592.
- Roe, J.S., Hwang, C.I., Somerville, T.D.D., Milazzo, J.P., Lee, E.J., Da Silva, B., Maiorino, L., Tiriak, H., Young, C.M., Miyabayashi, K., et al. (2017). Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. *Cell* **170**, 875–888.e20.
- Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., Citrin, D.E., Restifo, N.P., Robbins, P.F., Wunderlich, J.R., et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* **17**, 4550–4557.
- Sarmento, O.F., Digilio, L.C., Wang, Y., Perlin, J., Herr, J.C., Allis, C.D., and Coonrod, S.A. (2004). Dynamic alterations of specific histone modifications during early murine development. *J. Cell Sci.* **117**, 4449–4459.
- Seberg, H.E., Van Otterloo, E., Loftus, S.K., Liu, H., Bonde, G., Sompallae, R., Gildea, D.E., Santana, J.F., Manak, J.R., Pavan, W.J., et al. (2017). TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF. *PLoS Genet.* **13**, e1006636.
- Shen, L., Shao, N., Liu, X., and Nestler, E. (2014). ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases. *BMC Genomics* **15**, 284.
- Shields, B.D., Mahmoud, F., Taylor, E.M., Byrum, S.D., Sengupta, D., Koss, B., Baldini, G., Ransom, S., Cline, K., Mackintosh, S.G., et al. (2017). Indicators of responsiveness to immune checkpoint inhibitors. *Sci. Rep.* **7**, 807.
- Simmons, J.L., Pierce, C.J., Al-Ejeh, F., and Boyle, G.M. (2017). MITF and BRN2 contribute to metastatic growth after dissemination of melanoma. *Sci. Rep.* **7**, 10909.
- Simon, J.A., and Lange, C.A. (2008). Roles of the EZH2 histone methyltransferase in cancer epigenetics. *Mutat. Res.* **647**, 21–29.
- Sinnberg, T., Levesque, M.P., Krochmann, J., Cheng, P.F., Ikenberg, K., Meraz-Torres, F., Niessner, H., Garbe, C., and Busch, C. (2018). Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. *Mol. Cancer* **17**, 59.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**, 15545–15550.
- Tawbi, H.A., Forsyth, P.A., Algazi, A., Hamid, O., Hodi, F.S., Moschos, S.J., Khushalani, N.I., Lewis, K., Lao, C.D., Postow, M.A., et al. (2018). Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *N. Engl. J. Med.* **379**, 722–730.
- Terranova, C., Tang, M., Orouji, E., Maitituoheti, M., Raman, A., Amin, S., Liu, Z., and Rai, K. (2018). An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues. *J. Vis. Exp.* **134**, 56972.
- Theveneau, E., and Mayor, R. (2012). Neural crest delamination and migration: from epithelium-to-mesenchyme transition to collective cell migration. *Dev. Biol.* **366**, 34–54.
- Thumar, J., Shahbazian, D., Aziz, S.A., Jilaveanu, L.B., and Kluger, H.M. (2014). MEK targeting in N-RAS mutated metastatic melanoma. *Mol. Cancer* **13**, 45.
- Tsao, H., Chin, L., Garraway, L.A., and Fisher, D.E. (2012). Melanoma: from mutations to medicine. *Genes Dev.* **26**, 1131–1155.
- Vallianatos, C.N., and Iwase, S. (2015). Disrupted intricacy of histone H3K4 methylation in neurodevelopmental disorders. *Epigenomics* **7**, 503–519.
- Vardabasso, C., Hake, S.B., and Bernstein, E. (2015). Histone variant H2A.Z: A novel driver of melanoma progression. *Mol. Cell. Oncol.* **3**, e1073417.
- Verma, S.K., Tian, X., LaFrance, L.V., Duquenne, C., Suarez, D.P., Newlander, K.A., Romeril, S.P., Burgess, J.L., Grant, S.W., Brackley, J.A., et al. (2012). Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. *ACS Med. Chem. Lett.* **3**, 1091–1096.
- Voigt, P., Tee, W.W., and Reinberg, D. (2013). A double take on bivalent promoters. *Genes Dev.* **27**, 1318–1338.
- Weisenberger, D.J. (2014). Characterizing DNA methylation alterations from The Cancer Genome Atlas. *J. Clin. Invest.* **124**, 17–23.
- Wu, J.N., and Roberts, C.W. (2013). ARID1A mutations in cancer: another epigenetic tumor suppressor? *Cancer Discov.* **3**, 35–43.
- Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137.
- Zingg, D., Debbache, J., Schaefer, S.M., Tuncer, E., Frommel, S.C., Cheng, P., Arenas-Ramirez, N., Haeusel, J., Zhang, Y., Bonalli, M., et al. (2015). The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. *Nat. Commun.* **6**, 6051.
- Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R.A., Antunes, A.T., Haeusel, J., Sommer, L., and Boyman, O. (2017). The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. *Cell Rep.* **20**, 854–867.
- Zipser, M.C., Eichhoff, O.M., Widmer, D.S., Schlegel, N.C., Schoenewolf, N.L., Stuart, D., Liu, W., Gardner, H., Smith, P.D., Nuciforo, P., et al. (2011). A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. *Pigment Cell Melanoma Res.* **24**, 326–333.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
anti-EZH2 (Cell Signaling; 5246S)	Cell Signaling	CAT#5246S; RRID:AB_10694683
anti-SUZ12	Active Motif	CAT#39057; RRID:AB_2614929
anti-ZEB1	Millipore Sigma	CAT#ABD53; RRID:N/A
H3K4me3	Abcam	CAT#ab8580; RRID:AB_306649
H3K4me1	Abcam	CAT#ab8895; RRID:AB_306847
H3K9me3	Abcam	CAT#ab8898; RRID:AB_306848
H3K27ac	Abcam	CAT#ab4729; RRID:AB_2118291
H3K27me3	Abcam	CAT#ab6002; RRID:AB_305237
H3K79me2	Abcam	CAT#ab3594; RRID:AB_303937
anti-H3	Cell Signaling	CAT#4499S; RRID:AB_10544537
anti-Beta-actin	Cell Signaling	CAT#4967S; RRID:AB_330288
anti-SNAI1	Abcam	CAT# ab216347 RRID:N/A
anti-NRAS	Abcam	CAT#ab77392 RRID:AB_1524048
anti-Vimentin	Cell Signaling	CAT#5741 RRID:AB_10695459
Anti-rabbit IgG, horseradish peroxidase (HRP)-linked	Cell Signaling	CAT#7074S; RRID:AB_2099233
Horse anti-mouse IgG, HRP-linked	Cell Signaling	CAT#7076S RRID:AB_330924
<b>Chemicals, peptides, and recombinant proteins</b>		
GSK-126 1346574-57-9, 5 mg	Caymen Chemical	CAT#NC0761027
GSK-126, 500mg	MedChemExpress	CAT# HY-13470
Vemurafenib	MedChemExpress	CAT# HY-12057
Trametinib	MedChemExpress	CAT# HY-10999A
3-Deazaneplanocin A	Caymen Chemical	CAT#102052-95-9
NRAS sgRNA CRISPR/Cas9 All-in-one vector	ABM	CAT# 321511110595
Scrambled sgRNA CRISPR/Cas9 All-in-one vector	ABM	CAT#K010
miniProtease inhibitor	Roche	CAT#11836153001
Dynabeads Protein G for Immunoprecipitation	Thermo Fisher	CAT#10009D
Solid-Phase Reversible Immobilization (SPRI) beads; Reagent, SPRIselect, 450mL	Beckman-Coulter	CAT#B23319
Dulbecco's Phosphate Buffered Saline (DPBS) (Ca <sup>2+</sup> - and Mg <sup>2+</sup> -free)	Millipore Sigma	CAT#D8537-500ML
HBSS (Ca <sup>2+</sup> - and Mg <sup>2+</sup> -free)	Thermo Fisher	CAT#88284
Invitrogen UltraPure 0.5M EDTA, pH 8.0	Thermo Fisher	CAT#15575020
L-Glutamine (200 mM)	Millipore Sigma	CAT#25030081
HEPES solution	Millipore Sigma	CAT#H0887-100ML
Sodium dodecyl sulfate (SDS)	Sigma-Aldrich	CAT#74255
Lithium Chloride	Sigma-Aldrich	CAT#746460
Sodium Chloride	Sigma-Aldrich	CAT#S7653
Tris-HCL 1M pH 8.0	Teknova	CAT#T1080
Glycine	Sigma-Aldrich	CAT#G8898
Pierce 16% Formaldehyde (w/v), Methanol-free	Thermo Fisher	CAT#28908
Bovine Serum Albumin – IgG free	Millipore Sigma	CAT#A2058 –5G
RNase A	Invitrogen	CAT#12091021

(Continued on next page)

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Proteinase K	Invitrogen	CAT#100005393
RIPA buffer	Boston BioProducts	CAT# BP-115
2x Laemmli buffer	Bio-Rad	CAT#1610737
4-20% Criterion TGX Stain-Free gels	Bio-Rad	CAT#5678094
Amersham ECL Western Blotting Detection Reagent	GE Healthcare	CAT#RPN2106
SuperSignal West Pico Plus Chemiluminescent substrate	Thermo Fisher	CAT#34577
SuperSignal West Dura Extended Duration substrate	Thermo Fisher	CAT#34075
Restore Western Blot stripping buffer	Thermo Fisher	CAT#21063
<b>Critical commercial assays</b>		
NEBNext® Multiplex Oligos (index primer – Set1)	New England Biolabs	CAT#E7335L
NEBNext® Multiplex Oligos (index primer – Set2)	New England Biolabs	CAT#E7500L
NEBNext® Ultra II DNA Library Prep Kit for Illumina®	New England Biolabs	CAT#E7645L
High Sensitivity D1000 Reagents	Agilent Technologies	CAT#5067-5585
Invitrogen Qubit dsDNA HS Assay Kit	Thermo Fisher	CAT#Q32851
TruSeq DNA LT Sample Prep Kit	Illumina	CAT# FC-121-2001 and FC-121-2002
DynaMag – 96 Side Skirted	Invitrogen	CAT#120.27
Matrigel-coated well inserts	Corning	CAT#08774122
<b>Deposited data</b>		
Raw and analyzed data	This paper	GSE134043
Human reference genome (UCSC hg19)	Illumina iGenome	<a href="http://bowtie-bio.sourceforge.net/index.shtml">http://bowtie-bio.sourceforge.net/index.shtml</a>
Ensemble annotated human genome features	Ensembl	<a href="https://genome.ucsc.edu/cgi-bin/hgTables">https://genome.ucsc.edu/cgi-bin/hgTables</a>
<b>Experimental models: Cell lines</b>		
Melanoma Short Term Cultures	This paper	N/A
<b>Experimental models: Organisms/strains</b>		
Mouse: Crl:NU(lco)-Foxn1 <sup>nu</sup>	Charles River	Strain code: 620
<b>Software and algorithms</b>		
Raw ChIP read processing: FastQC	<a href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</a>	<a href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</a>
Genome alignment: Bowtie (v1.1.2)	Langmead et al., 2009	<a href="http://bowtie-bio.sourceforge.net/index.shtml">http://bowtie-bio.sourceforge.net/index.shtml</a>
Duplicate read removal: SAMBLASTER	Faust and Hall, 2014	<a href="https://github.com/GregoryFaust/samblaster">https://github.com/GregoryFaust/samblaster</a>
Downsampling: samtools (v1.5)	Li et al., 2009	<a href="http://samtools.sourceforge.net/">http://samtools.sourceforge.net/</a>
ChIP-seq library visualization: deepTools (v2.4.0)	Ramírez et al., 2016	<a href="https://deeptools.readthedocs.io/en/develop/">https://deeptools.readthedocs.io/en/develop/</a>
ChIP-seq peak calling: Model-based analysis of ChIP-seq (MACS) (v1.4.2) and (v2.1.0)	Zhang et al., 2008	<a href="http://liulab.dfci.harvard.edu/MACS/00README.html">http://liulab.dfci.harvard.edu/MACS/00README.html</a>
Galaxy/Cistrome	Liu et al., 2011	<a href="http://cistrome.org/ap/root">http://cistrome.org/ap/root</a>
Gene body heatmaps and average density plots: ngs.plot	Shen et al., 2014	<a href="https://github.com/shenlab-sinai/ngsplot">https://github.com/shenlab-sinai/ngsplot</a>
Chromatin state patterns: ChromHMM	Ernst and Kellis, 2012	<a href="http://compbio.mit.edu/ChromHMM/">http://compbio.mit.edu/ChromHMM/</a>
Gene Set Enrichment Analysis (MSigDB)	Subramanian et al., 2005	<a href="https://www.gsea-msigdb.org/gsea/msigdb/index.jsp">https://www.gsea-msigdb.org/gsea/msigdb/index.jsp</a>
RStudio		<a href="https://www.rstudio.com/">https://www.rstudio.com/</a>
Bedtools	Quinlan and Hall., 2010	<a href="https://bedtools.readthedocs.io/en/latest/">https://bedtools.readthedocs.io/en/latest/</a>
Bedops	Neph et al., 2012	<a href="https://bedops.readthedocs.io/en/latest/">https://bedops.readthedocs.io/en/latest/</a>

## RESOURCE AVAILABILITY

### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kunal Rai ([krai@mdanderson.org](mailto:krai@mdanderson.org)).

### Materials availability

This study did not generate new unique reagents.

### Data and code availability

The ChIP sequencing data has been deposited in the NCBI GEO BioProject database with the following accession number GSE134043. ChIP-seq data for histone modifications in ESCs, germ cells and melanocytes were downloaded from <ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/roadmap/epigenomics/>. ChIP-seq data for SUZ12 and EZH2 was downloaded from the NCBI GEO BioProject database with the following accession number GSE29611. Code used in this study is available on <https://rpubs.com/cjt5> and <https://github.com/sccallahán/ChromXploreR>.

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Human subjects

Melanoma tumors were obtained from the Melcore tumor bank at MD Anderson Cancer Center as per an approved Institutional Review Board protocol (IRB #PA12-0305). The details of the patient samples are available in [Table S1](#).

### Animals

Female mice (strains: Crl:NU(lco)-Foxn1<sup>nu</sup> Charles river, strain code 620) were purchased, bred in house, and maintained at 72°F ± 2°F on a 12h light/dark cycle. Four- to six-week-old aged females were randomly assigned with five mice housed together per cage. Animals were provided *ad libitum* access to food and water. All the animal studies were performed as per an approved Institutional Animal Care and Use Committee protocol (IACUC #00001411-RN01).

### Cell lines

Melanoma short term cultures were generated from metastatic tumor specimens as part of the Adoptive T cell Therapy Clinical Program at the University of Texas, MD Anderson Cancer Center (LAB06-0755 and 2004-0069), as previously described ([Oba et al., 2018](#); [Besser et al., 2009](#); [Park et al., 2017](#)). Briefly a tumor specimen from metastatic tumor was collected and incubated with an enzymatic digestion cocktail (0.375% collagenase type I, 75 μg/ml hyaluronidase and 250 U/mL DNase I) in tumor digestion medium (RPMI, 10 mM of HEPES, 1x Penicillin-Streptomycin and 20 μg/mL of Gentamicin; GIBCO/Invitrogen) in a humidified incubator at 37°C with 5% CO<sub>2</sub> and with a gentle rotation for 2-3h to obtain a single cell suspension. The tumor digest was filtered through a 70-μm filter, washed, and re-suspended in a serum free media, which was then plated in one well of a 6-well culture plate and incubated at 37°C. After 24h, the media was replaced with fresh tumor media, comprised of RPMI with GlutaMAX, 10% FBS, Penicillin/Streptomycin, Gentamicin, β-mercaptoethanol (50 μM, GIBCO/Invitrogen), HEPES (10 mM), and insulin-selenium-transferin (5 μg/ml, GIBCO/Invitrogen). Cells were grown in enriched DMEM/F12 culture media (GIBCO/Invitrogen) supplemented with all growth factors including 10% FBS, sodium pyruvate (1mM), insulin-selenium-transferin, MycoZap-PR (Lonza), HEPES (10mM) and β-Mercaptoethanol. Once enough cells were grown, the purity of the tumor was tested using a melanoma tumor surface marker (MCSP-1) by flow cytometry. Cultures were deemed established when the cells stained positive for a melanoma tumor marker (MCSP-1) and negative for a fibroblast marker (CD90). Appropriate serum starving was performed to eliminate fibroblasts. All cell lines were tested for mycoplasma using MycoAlert detection kit (Lonza), and fingerprinted by STR fingerprinting, and validated by comparing with matched blood samples. A few passages after a pure tumor line was established, the cells were cryopreserved and kept in stocks in liquid nitrogen until use.

### Isogenic mutant melanocytes

*BRAF*<sup>V600E</sup> or *NRAS*<sup>Q61K</sup> melanocytes were generated as described in [Fiziev et al. \(2017\)](#), [Garraway et al. \(2005\)](#), and [Rai et al. \(2015\)](#). Briefly, normal melanocytes were immortalized by TERT expression and partially-transformed by overexpression of dominant negative TP53 and CDK4<sup>R24C</sup>. Lentiviral exogenous *BRAF*<sup>V600E</sup> or *NRAS*<sup>Q61K</sup> derivatives were then expressed to generate isogenic melanocyte pairs.

## METHOD DETAILS

### Chromatin immunoprecipitation assays

ChIP assays were performed as described previously ([Terranova et al., 2018](#)). Briefly, for tumor samples 50mg of tissue (~7mg/IP) were manually dissociated in 2mL of Hanks Balanced Salt Solution (HBSS) using a sterile razor blade. An additional 8mL of HBSS was added and tissue was further disassociated using a MACS homogenizer with the follow cycles; h\_tumor\_01.01, h\_tumor\_02.01,

h\_tumor\_03.01 and m\_heart\_02.01. For cell lines,  $2 \times 10^7$  cells were harvested by scraping. Tumors and cell lines were cross-linked with 1% (wt/vol) formaldehyde for 10 min at 37°C with shaking. After quenching with 150 mM glycine for 5 min at 37°C with shaking, cells were washed twice with ice-cold PBS and frozen at  $-80^\circ\text{C}$  for further processing. Cross-linked pellets were thawed and lysed on ice for 30 min in CHIP harvest buffer (12 mM Tris-Cl, 1 × PBS, 6 mM EDTA, 0.5% SDS) with protease inhibitors (Sigma). Lysed cells were sonicated with a Bioruptor (Diagenode) to obtain chromatin fragments (~200–500 bp) and centrifuged at  $15,000 \times g$  for 15 min to obtain a soluble chromatin fraction. In parallel with cellular lysis and sonication, antibodies ( $5 \mu\text{g}/3 \times 10^6$  cells) were coupled with 30  $\mu\text{L}$  of magnetic protein G beads in binding/blocking buffer (PBS + 0.1% Tween + 0.2% BSA) for 2h at 4°C with rotation. Antibodies used for CHIP included anti-H3K4me3 (Abcam; ab8580), anti-H3K4me1 (Abcam; ab8895), anti-H3K27ac (Abcam; ab4729), anti-H3K79me2 (Abcam; ab3594), anti-H3K27me3 (Abcam; ab6002) and anti-H3K9me3 (Abcam; ab8898). Soluble chromatin was diluted five times using CHIP dilution buffer (10 mM Tris-Cl, 140 mM NaCl, 0.1% DOC, 1% Triton X, 1 mM EDTA) with protease inhibitors and added to the antibody-coupled beads with rotation at 4°C overnight. After washing, samples were treated with elution buffer (10 mM Tris-Cl, pH 8.0, 5 mM EDTA, 300 mM NaCl, 0.5% SDS), RNase A, and Proteinase K, and cross-links were reversed overnight at 37°C. Immune complexes were then washed five times with cold RIPA buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA, pH 8.0, 140mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1% DOC), twice with cold high-salt RIPA buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA, pH 8.0, 500mM NaCl, 1% Triton X-100, 0.1% SDS, 0.1% DOC), and twice with cold LiCl buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA, pH 8.0, 250mM LiCl, 0.5% NP-40, 0.5% DOC). CHIP DNA was purified using AMPure XP beads (Agencourt) and quantified using the Qubit 2000 (Invitrogen) and Bioanalyzer 1000 (Agilent). Libraries for Illumina sequencing were generated following the New England BioLabs (NEB) Next Ultra DNA Library Prep Kit protocol. A total of 10 cycles were used during PCR amplification for the generation of all CHIP-seq libraries. Amplified CHIP DNA was purified using double-sided AMPure XP to retain fragments (~200–500 bp) and quantified using the Qubit 2000 and Bioanalyzer 1000 before multiplexing.

### CHIP-seq data processing

Raw fastq reads for all CHIP-seq experiments were processed using a snakemake based pipeline <https://github.com/crazyhottommy/pyflow-CHIPseq>. Briefly, raw reads were first processed using FastQC (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and uniquely mapped reads were aligned to the hg19 reference genome using Bowtie version 1.1.2 (Langmead et al., 2009). Duplicate reads were removed using SAMBLASTER (Faust and Hall, 2014) before compression to bam files. To directly compare CHIP-seq samples uniquely mapped reads for each mark were downsampled per condition to 18 million, sorted and indexed using samtools version 1.5 (Li et al., 2009). To visualize CHIP-seq libraries on the IGV genome browser, we used deepTools version 2.4.0 (Ramírez et al., 2016) to generate bigWig files by scaling the bam files to reads per kilobase per million (RPKM). Super CHIP-seq tracks were generated by merging bam files from each cancer type, sorting and indexing using samtools and scaling to RPKM using deepTools.

### Chromatin state analysis

ChromHMM (Ernst and Kellis, 2012) was used to identify combinatorial chromatin state patterns based on the histone modifications studied. Normalized bam files were converted to bed files and binarized at a 1000bp resolution using the BinarizeBed command. We specified that ChromHMM should learn a model based on 18 chromatin states. As we considered models between 2 and 30 chromatin states, we annotated an 18-state model since it is large enough to identify non-redundant functional elements encompassing canonical chromatin states that were not captured using lower state models. To determine chromatin state differences between different groups we used a two-step process. First, using the segmentation calls from the ChromHMM output the entire genome is divided into non-overlapping windows of 10 Kb. We next count the number of times a chromatin state is observed in each of the 10 Kb windows and obtain a frequency matrix for each state in the ChromHMM model (E1-E18). In the second step, low variable genomic loci are removed from the frequency matrix and significant differences between two groups of samples types are calculated by using a nonparametric Mann Whitney Wilcoxon test with a P value < 0.05 for each state separately.

### Correlation of copy number from CHIP-seq and SNP array

SKCM TCGA copynumber data were downloaded by TCGAbiolinks (Colaprico et al., 2016). Copy number analysis for ChIPseq was carried out using copywriter (Kuilman et al., 2015), which uses off-target reads for accurate copy number detection. The CHIP-seq input files were used, which represent low-pass whole genome sequencing datasets. Bin size of 200kb was used for analysis. The copy number of each gene was determined by overlapping the genes with the segmentation files from ChIPseq and SNP array, respectively. The Pearson correlation of the copy number of all genes among samples was calculated and plotted in heatmap by ComplexHeatmap.

### Correlation of RNA expression and chromatin state data

SKCM TCGA RNaseq data were downloaded by TCGAbiolinks (Colaprico et al., 2016). TPM (transcript per million) value was calculated from raw counts by scaling to the gene length first and then the library size. For each gene in a sample, the transcription start site is overlapped with the chromatin state segmentation file to determine the state of that gene. The expression values (TPM) for all genes and all samples are then combined and spilt by categories (18) of chromatin states. A boxplot is plotted for each chromatin state.



### Correlation of DNA methylation and chromatin state data

SKCM TCGA 450k DNA methylation data were downloaded by TCGAbiolinks (Colaprico et al., 2016). For each sample and each chromatin state segmentation bin, the average of beta values from the DNA methylation data were calculated for each bin. The average values of all bins from all samples are combined and then split by categories (18) of chromatin states. A boxplot is plotted for each chromatin state.

### Identification and visualization of ChIP-seq associated loci

We used Model-based analysis of ChIP-seq (MACS) version 1.4.2 (Zhang et al., 2008) peak calling algorithm to identify H3K4me3 (p value of 1e-5) and MACS version 2.1.0 to identify H3K27me3 (p value of 1e-5) enrichment over “input” background. Bivalent sites were identified by overlapping H3K4me3 with H3K27me3 or H3K9me3 by a minimum of 1bp using intersectBed (Quinlan and Hall, 2010). Identification of H3K27me3 peaks in isogenic mutant melanocytes were identified using MACS version 1.4.2. Bivalent polycomb-heterochromatin regions were identified by overlapping the H3K4me3+H3K27me3 output with H3K9me3 by a minimum of 1bp. Common sites were identified using bedops (Neph et al., 2012) with the following command; `cat *bed | sort-bed - | bedmap-count-echo-delim '\t' - | uniq | awk '$1 >= x' | cut -f2- > samplename_common.bed`. This was based on peaks present in BRAF = 7/13, NRAS = 2/4, WT = 2/3, MSTC = 5/10, CCLE = 8/16 and melanocytes = 2/2 samples. Final peaksets used for downstream analysis were generated using mergeBed. Unique BRAF, NRAS, WT and melanocyte peaks for bivalent domains were identified using the concatenate, cluster and subtract tools from the Galaxy/Cistrome web-based platform (Liu et al., 2011). To identify sites that were bivalent in melanocytes but active in melanoma tumors, and visa-versa, common H3K27me3 sites were subtracted from the opposing bivalent site in each comparison.

### Identification of broad H3K4me3 domains

Broad H3K4me3 domains for all samples were identified using MACS2.1.0 with the broad setting (p value of 1e-5) followed by merging adjacent peaks within 1kb using mergeBed (Quinlan and Hall, 2010; Subramanian et al., 2005). We determined the optimal distance to merge adjacent peaks based on the number of broad H3K4me3 domains at distance thresholds between 1kb through 10kb in each mutational subtype. Broad H3K4me3 domains were further classified as peaks that extended at least 4x (> 4kb) beyond that of a typical H3K4me3 domain (0.2kb-1kb). Final peaksets for common sites broad and non-broad H3K4me3 and H3K27me3 domains were defined as in identification and visualization of ChIP-seq associated loci (BRAF = 7/13, NRAS = 2/4, WT = 2/3 and melanocytes = 2/2).

### Assigning associated loci to genes

A list of Ensembl genes was obtained from the UCSC Table browser (<http://genome.ucsc.edu/>). Promoters were defined as  $\pm$  10kb from the transcription start site (TSS) and genic regions were identified as +10kbTSS to the transcription end site (TES). Peaks were assigned to genes if they overlapped the promoter or genic region by a minimum of 1bp using intersectBed. Gene body heatmaps and average density plots were generated using ngs.plot (Shen et al., 2014).

### Gene set enrichment analysis

Gene Set Enrichment Analysis (GSEA) was performed using GSEA/MsigDB (Subramanian et al., 2005) HALLMARK and KEGG pathways based on ensemble gene lists from peaks within  $-10$ kb-TES for bivalent domains and  $\pm$  10kbTSS for broad H3K4me3 domains. All pathways are significant based on FDR q-value.

### RNA-sequencing data processing

For TCGA data, raw counts were obtained from TCGAbiolinks (Colaprico et al., 2016) in R (<https://www.rstudio.com/>) and transformed to TPM. For the melanoma tumor data in addition to TCGA, raw microarray expression levels were obtained from GSE15605. For Roadmap data, raw counts were obtained from <http://www.roadmapepigenomics.org/> and transformed to TPM. For melanocyte data in addition to Roadmap, raw counts were obtained from PRJNA421623 and SRP002621. For all RNA-seq boxplots based on count data, gene expression values were normalized using the quantile normalization function in R.

### Proliferation assays

Cell proliferation was measured and quantified using IncuCyte ZOOM system (Essen Biosciences). Briefly, after 14 days of GSK-126 (1  $\mu$ M, 2  $\mu$ M, 3  $\mu$ M) or DMSO treatment melanoma short-term cultures MSTC-2125 and MSTC-2770 cells were seeded at a density of 5,000 cells per well in 96-well plates. Cell proliferation was measured for 155h and media for GSK-126 and DMSO treatment was replaced every third day. Cell proliferation is plotted as confluence percentage.

### Boyden Chamber invasion assays

Boyden Chamber assays were performed according to manufacturer’s protocol after 14 days of GSK-126 (1  $\mu$ M, 2  $\mu$ M, 3  $\mu$ M) or DMSO treatment of melanoma short-term cultures. For 3-Deazaneplanocin A (DZNep), MSTC-2125 were treated for 14 days (1  $\mu$ M, 2  $\mu$ M, 3  $\mu$ M) and MSTC-2770 were treated for 10 days (1  $\mu$ M, 2  $\mu$ M). Briefly, cells were washed 3-times with “empty” media (serum and antibiotic free) and 100,000 cells were subjected to Matrigel-coated well inserts (08774122, Corning). Growth media was used as a chemoattractant for 24h in Matrigel wells. For reference wells 100,000 cells were plated in growth media. Cells in Matrigel

and reference wells were washed with 1% PBS and incubated with 10% formalin for 10 minutes. Cells were washed again with 1% PBS and incubated in crystal violet staining for 10 minutes. For quantitation, the invaded cells and the control plated cells were de-stained in 10% acetic acid for 15 minutes and calorimetry was performed at 590nm. The ratio of invaded cells to control cells was plotted to graph relative invasion.

### Immunoblot analysis

Melanoma short-term cultures ( $1 \times 10^7$  cells) were washed with ice-cold PBS then lysed for 30 minutes at 4°C with agitation in RIPA buffer (Boston BioProducts; BP-115) supplemented with a Roche cOmplete, Mini, EDTA-free protease inhibitor cocktail (Millipore Sigma; 11836170001). Malme-3M cells were treated for 14 days with GSK-126 (1  $\mu$ M, 2  $\mu$ M, 3  $\mu$ M) or DMSO before lysis. Lysate was centrifuged at 4°C for 15 minutes at 15,000rpm. The pellet was discarded and protein was quantified using BCA assay. Samples were supplemented with 2x Laemmli buffer (Bio-Rad; 1610737) and 2-mercaptoethanol, heated for 5 min at 95°C and loaded on 4%–20% Criterion TGX Stain-Free gels (Bio-Rad; 5678094). Protein expression was examined by western blot using anti-EZH2 (Cell Signaling; 5246S), anti-SUZ12 (Active Motif; 39057), anti-ZEB1 (Millipore Sigma; ABD53), anti-SNAI1 (ab216347), anti-NRAS (ab77392), anti-H3 (CST; 4499S) Beta-actin (CST; 4967S), goat anti-rabbit IgG-HRP (CST; 7074S) and horse anti-mouse IgG-HRP (CST; 7076S). Reactive bands were detected by Amersham ECL Western Blotting Detection Reagent (RPN2106, GE Healthcare), SuperSignal West Pico Plus Chemiluminescent substrate (Thermo; 34577) or SuperSignal West Dura Extended Duration substrate (Thermo; 34075). The membranes were reprobed after incubation in Restore Western Blot stripping buffer (Thermo; 21063). ImageJ software was utilized to measure image densitometry of bands as previously described (Janes, 2015). Western blot results were representative of at least three independent biological replicates.

### Acid extraction of histones

Melanoma short-term cultures ( $1 \times 10^7$  cells) were treated for 14 days with GSK-126 (1  $\mu$ M, 2  $\mu$ M, 3  $\mu$ M) or DMSO and then washed with ice-cold PBS then lysed for 10 minutes at 4°C with agitation in Triton X-100 extraction buffer supplemented with a Roche cOmplete, Mini, EDTA-free protease inhibitor cocktail (Millipore Sigma; 11836170001). For 3-Deazaneplanocin A (DZNep), MSTC-2770 were treated for 10 days (1  $\mu$ M, 2  $\mu$ M). Lysate was centrifuged at 4°C for 10 minutes at 6,500rpm. Supernatant was discarded and the pellet was washed with TEB and centrifuged as above. Supernatant was discarded and the pellet was resuspended in 0.2N HCl and histones were extracted overnight at 4°C. Samples were again centrifuged and supernatant was neutralized with 2M NaOH at a 1:10 volume. Protein was quantified using Bradford assay and protein expression was examined by western blot using anti-H3K27me3 (Abcam; ab6002) and anti-H3 (CST; 4499S).

### Stable cell line generation

For lenti packaging, 5  $\mu$ g of *NRAS* sgRNA CRISPR/Cas9 All-in-one vector (ABM: 321511110595) or 5  $\mu$ g of *Scrambled* sgRNA CRISPR/Cas9 All-in-one vector (ABM: K010) was transfected together with packaging plasmids (5  $\mu$ g) in HEK293T cells using Lipofectamine 3000 according to manufacturer's instructions. For transduction, lentivirus with DMEM media + 10  $\mu$ g of polybrene was reversed transduced with MSTC-2125 cells and transgene selection was performed using 3  $\mu$ g/mL of puromycin.

### Quantitative PCR

qRT-PCR assays were performed after 14 days of GSK-126 (1  $\mu$ M, 2  $\mu$ M, 3  $\mu$ M) or DMSO treatment of melanoma cell lines. Total RNA was isolated using RNeasy Mini Kit (QIAGEN) and 500ng of RNA from each sample was reverse transcribed using SuperScript VILO cDNA Synthesis Kit (Thermo Fisher). qRT-PCR was performed with 2  $\mu$ L of undiluted cDNA in triplicate for each primer set. *GAPDH* was used as a housekeeping gene and data was plotted and quantified using <https://peerj.com/articles/4473>.

### Immunohistochemistry for patient tissue microarrays

Immunohistochemical stains were performed on 6 stage III and IV melanoma tissue microarrays (TMA) (Ekmekcioglu et al., 2016; Iida et al., 2017). After heat mediated epitope retrieval at pH 8.0 for 20 min, the sections were incubated with mouse monoclonal SUZ12, Clone 3D10 (1:500, ThermoFisher) and mouse monoclonal EZH2, Clone AC22 (1:200, Cell signaling Technology). IHC staining was performed using a Leica Bond Max automated stainer (Leica Biosystems, Buffalo Grove, IL). The IHC reaction was performed using Leica Bond Polymer Refine detection kit (Leica Biosystems). Immunoreactive cells were visualized using diaminobenzidine (DAB) as chromogen followed by counterstaining with hematoxylin. All IHC slides were scanned using an Aperio AT Turbo (Leica Biosystems). The scoring was performed by a pathologist (RL) using direct microscope evaluation. EZH2 and SUZ12 expression was considered positive when nuclear staining was present on tumor cells and it was evaluated by H-score, which assesses the percentage of positive cells (0 to 100) multiplied by the intensity of staining (0 to 3+), with a total score ranging from 0 to 300. H-scores for EZH2 or SUZ12 in patients harboring an *NRAS* or *BRAF* mutation were compared using a t test.

### Immunohistochemistry for murine tumor samples

Tumors were fixed in formalin for 24 hours, paraffin embedded, sectioned and stained according to standard procedures. Briefly, slides were baked at 60°C for 1 hour then deparaffinized and rehydrated. After antigen retrieval in citrate buffer, endogenous peroxidases were inactivated by 3% hydrogen peroxide. Non-specific signals were blocked using Rodent Block M (Biocare RBM961).

Then slides were stained using VIM antibody (Cell Signaling; 5741) overnight at 4°C. After overnight incubation, the slides were washed and incubated with secondary antibody (HRP-polymers, Biocare RMR622) for 30 min at room temperature. The slides were washed and stained with DAB substrate (ThermoFisher Scientific). The slides were then counterstained with hematoxylin and mounted with mounting medium (Richard-Allan Scientific). Cells were counted using imageJ based on a minimum of 9 20x images from each sample. P values were calculated using a wilcoxon test.

### **In vivo assays**

NRAS- and BRAF- mutant melanoma short term cultures (MSTC) were transplanted in the flanks of NUDE mice and observed for tumor induction. Once visible tumors were formed, the mice were randomly distributed in 4 groups and injected with Vehicle, GSK-126 (150mg/kg), MEK inhibitor (1mg/kg), or a combination of the two drugs intraperitoneally every other day in 5 mice per arm. For BRAF inhibitors, mice were injected with Vehicle or BRAF-inhibitor (50mg/kg) every other day in 4 mice per arm. Tumors were measured every third day and the volume was calculated using  $0.5 \times L \times W \times H$  formula. P values were calculated by a paired t test for each time point using graph pad prism.

### **QUANTIFICATION AND STATISTICAL ANALYSIS**

For chromatin state analysis and all RNA-seq comparisons significant differences between groups was calculated using a Wilcoxon test. For western blotting analysis (Figures 5D and 5E), relative density was quantified using ImageJ software, and the values of the target proteins were normalized to b-Actin. Error bars represent mean  $\pm$  SEM. For all *in-vivo* data, tumors were measured every third day and the volume was calculated using  $0.5 \times L \times W \times H$  formula. p values were calculated by a paired t test for each time point using graph pad prism. For immunohistochemistry of patient tissue microarrays, scoring was performed by a pathologist using direct microscope evaluation. EZH2 and SUZ12 expression was considered positive when nuclear staining was present on tumor cells and it was evaluated by H-score. H-scores for EZH2 or SUZ12 in patients harboring an NRAS or BRAF mutation were compared using a t test. For immunohistochemistry of murine tumor samples, cells were counted using imageJ based on a minimum of 9 20x images from each treatment condition. p values were calculated using a wilcoxon test.